Methodology Report 2013
for the 2014 Access to Medicine Index
Acknowledgements

The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report:

**Funders**
- Bill & Melinda Gates Foundation
- UK Department for International Development (DFID)
- The Netherlands Ministry of Foreign Affairs

**Expert Review Committee**
- Hans Hogerzeil - Chair
- Natacha Dimitrijevic
- Marja Esveld
- Regina Kamoga
- Richard Laing
- Dennis Ross-Degnan
- Dilip Shah
- Peter Shelby

**Technical Subcommittees**
- Peter Beyer
- Esteban Burrone
- Jaime Espin
- Jennifer Dent
- Michele Forzley
- Javier Guzman
- Warren Kaplan
- Jillian Kohler
- Niranjan Konduri
- Prashant Yadav

**Additional contributors**
- Afshin Mehrpouya
- Rachelle Harris
- 'Strategic Access to Medicine Workshop' participants, May 2013, The Netherlands
- 'Stakeholder Dialogue: Ensuring quality affordable medicine in developing countries' participants, June 2013, Ghana
- 'Investor Dialogue' participants, September 2013, France
Methodology Report 2013
for the 2014 Access to Medicine Index

Access to Medicine Foundation
November 2013
Table of Contents

5 Introduction

6 Executive Summary

9 What we measure
10 Company Scope
12 Geographic Scope
15 Disease Scope
18 Product Type Scope

19 How we measure
20 Approach to weights and analysis
21 Strategic Pillars
22 Technical Areas
22 A General Access to Medicine Management
23 B Public Policy & Market Influence
24 C Research & Development
25 D Pricing, Manufacturing & Distribution
26 E Patents & Licencing
27 F Capability Advancement in Product Development & Distribution
28 G Product Donations & Philanthropic Activities

29 Refining the methodology
30 Developing the methodology
30 Internal and external review
31 Expert committee consultations
31 Considerations and outcomes

37 Indicators
38 A General Access to Medicine Management
40 B Public Policy & Market Influence
43 C Research & Development
46 D Pricing, Manufacturing & Distribution
49 E Patents & Licencing
51 F Capability Advancement in Product Development & Distribution
53 G Product Donations & Philanthropic Activities

55 Appendix 1: Review & Consultations
56 Stakeholder dialogue
57 Committee consultation process
58 Contributors to this report

59 Appendix 2: ICD-10 Coverage

65 Appendix 3: References, Definitions & Acronyms
66 References cited in the text of this report
67 Definitions
73 References cited in Definitions
76 Acronyms

List of figures

7 Figure 1 How we measure
11 Figure 2 Market cap & revenue of companies included in the 2014 Access to Medicine Index
13 Figure 3 Map of countries included in the 2014 Access to Medicine Index
17 Figure 4 DALYs of diseases in the 2014 Access to Medicine Index
20 Figure 5 How we measure
30 Figure 6 The Index cycle
56 Figure 7 Developing the methodology

List of tables

8 Table 1 What we measure
10 Table 2 List of companies included in the 2014 Access to Medicine Index - 21 companies
14 Table 3 List of countries included in the 2014 Access to Medicine Index - 106 countries
16 Table 4 List of diseases included in the 2014 Access to Medicine Index - 47 diseases
60 Table 5 ICD-10 Coverage
Introduction

As developers and manufacturers of life-saving products, the world's leading pharmaceutical companies play an important role in improving access to medicine for the world's poor. Through their own initiatives and in collaboration with other relevant stakeholders such as multi-lateral organisations, governments and the global health community, these companies are increasingly helping to address the access to medicine challenge.

In order to suitably capture the industry's progress in line with society's evolving expectations, the Access to Medicine Index methodology is systematically reviewed every two years. While maintaining as much consistency as possible for the purpose of trend analysis, the methodology is adjusted where needed. This report describes the methodology that will be used for the 2014 Access to Medicine Index, and highlights the refinements made since the previous report.
The methodology for the 2014 Access to Medicine Index remains largely the same as the methodology for the previous Index. The 2014 Index will use the same framework for analysis, which continues to be constructed along seven Technical Areas with indicators measured across four Strategic Pillars. The weights within the framework remain unchanged and most of the indicators remain the same, though the number of indicators has been reduced. The geographic scope and disease scope have been expanded.

How the methodology was updated
The Index is produced over a two-year cycle. In the first year, the Access to Medicine Foundation reviews the Index methodology on the basis of intensive expert stakeholder feedback and defines the methodology for the next Access to Medicine Index. An Expert Review Committee and Technical Subcommittees, which offer strategic guidance, stakeholder perspectives and technical expertise, are formally consulted during this process. In the second year, pharmaceutical company data is collected, analysed and published in the Access to Medicine Index report.

In 2013, the Index team began refining the methodology for the 2014 Index by conducting an extensive and rigorous quantitative and qualitative analysis of the methodology and data from past Indices. The Index team outlined key areas for methodological enhancement and in particular highlighted indicators to be retained for longitudinal trend analysis. The Index team then engaged with stakeholders to understand their multiple perspectives and to stay up-to-date on developments in the access to medicine landscape. Feedback was sought through an online survey, calls with individual companies, and three separate stakeholder meetings with pharmaceutical companies, investors, and experts in developing countries. Insights were incorporated into the review process and considered by the Technical Subcommittees and the Expert Review Committee.

What remains the same?
The 2014 Index uses the same framework for analysis as the 2012 Index, which allows for comparison and trend analysis. The framework continues to be constructed along the same seven Technical Areas, with indicators measured across the same four Strategic Pillars. The weights of these Technical Areas and Strategic Pillars for the 2014 Index also remain unchanged. Most of the indicators remain unchanged.

What has changed?
Several strategic changes have been made in order to stay up-to-date with developments in the pharmaceutical industry and the access to medicine landscape. A selection of these changes is outlined below.

Tailoring to local needs: In 2014 the analysis will be broadened to include an assessment of the extent to which companies tailor their access strategies to local expectations, needs and conditions. The 2014 Index will also place greater emphasis on how companies target local public health needs as part of their overall access strategy, their R&D strategy, pricing strategies and capability advancement initiatives.

Inequality as a third selection criterion for country scope: Widespread inequality of human development within countries often inhibits access to medicine for the poorest population segments. Therefore the Index has added the UN Inequality-Adjusted Human Development Index as third criterion for determining its geographic scope. This means that four higher-income countries with large numbers of people living in poverty (Brazil, Colombia, Ecuador and Venezuela) have been added to the geographic scope.
**Executive Summary**

**More meaningful measurements of affordability:** The focus of the pricing analysis will be shifted towards affordability rather than comparison of tiered pricing programmes. The Index will now capture all forms of equitable pricing strategies where companies include socio-economic needs and affordability in determining commercial prices in countries covered by the Index. It will also assess the rationale behind companies' equitable pricing strategies and seek disclosure of volume of sales to the poorest segments of the population.

**Tracking breaches worldwide:** The 2014 Index will include an assessment of company breaches of codes of conduct or laws on ethical marketing, lobbying, corruption, bribery or anti-competitive behaviour that occur anywhere in the world, not only in countries included in the Index. The reason for this change is that company policies and practices outside the Index geographic scope can affect access to medicine in countries covered by the Index.

**Refining some indicators and removing redundancies:** Based on quantitative analysis, stakeholder consultations and internal review, the indicators have undergone some minor refinements. In order to increase their robustness and take into account relevant new developments, several indicators have been added, combined, replaced or removed. Overall, the number of indicators decreased from 101 to 95 and some have been earmarked for longitudinal trend analysis.

**Refinements to what we measure**

**Companies:** The company scope for the 2014 Index was only changed to reflect splits, mergers or a change in the relevance of companies' products to the disease scope. The 2014 Index measures 21 companies, with the addition of AbbVie since the 2012 Index.
**Countries:** The addition of the development inequality criteria resulted in the inclusion of more countries in Latin America in 2014. Some other minor adjustments were made, bringing the total number of countries to 106.

**Diseases:** The disease scope has expanded from 33 to 47 conditions (plus birth control), largely based on new information on the global burden of disease. Chlamydia, schizophrenia and bipolar affective disorder have been added and all 17 WHO-classified neglected tropical diseases are now included, as are more maternal and neonatal conditions. Coverage of cirrhosis of the liver has been broadened to include chronic viral hepatitis.

**Product types:** The product type scope remains unchanged from the 2012 Index, covering medicines, microbicides, therapeutic and preventive vaccines, diagnostics, vector control products and platform technologies.

**Table 1**  
*What we measure*

<table>
<thead>
<tr>
<th>Company Scope</th>
<th>21 research-based pharmaceutical companies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geographic Scope</td>
<td>106 countries 84 World Bank-based (LIC and LMIC) 18 UN HDI-based (LDC and MHDC) 4 IHDI-based (HHDC)</td>
</tr>
<tr>
<td>Disease Scope</td>
<td>47 diseases 10 Highest burden communicable diseases 12 Highest burden non-communicable diseases 17 Neglected tropical diseases 8 Maternal and neonatal health conditions (plus birth control)</td>
</tr>
<tr>
<td>Product Type Scope</td>
<td>Medicines, vaccines, diagnostics, vector control products, microbicides and platform technologies</td>
</tr>
</tbody>
</table>
What we measure

The Access to Medicine Index measures pharmaceutical companies’ policies and practices in improving access to medicine across a specific range of countries, diseases and product types.
Company Scope

The Index assesses the world’s top research-based pharmaceutical companies with respect to their efforts in access to medicine. The size, resources and global reach of these companies give them unique opportunities to improve access to medicine through innovative strategies, technologies and initiatives in markets throughout the world.

The companies included are those with the highest market capitalisation and product portfolios most relevant to the countries and diseases covered by the Index. The company scope is updated each publication cycle to accommodate changes in product portfolios and market capitalisation – a commonly used indicator of net worth – as well as industry changes such as mergers, acquisitions and internal splits.

### Table 2  List of companies included in the 2014 Access to Medicine Index - 21 companies

<table>
<thead>
<tr>
<th>Ticker</th>
<th>Company</th>
<th>Country</th>
<th>Market cap (billion, USD)</th>
<th>Revenue (billion, USD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABT-N</td>
<td>Abbott Laboratories Inc.</td>
<td>USA</td>
<td>52.699</td>
<td>39.874</td>
</tr>
<tr>
<td>ABBV-N</td>
<td>AbbVie Inc.</td>
<td>USA</td>
<td>57.040</td>
<td>22.603</td>
</tr>
<tr>
<td>4503-TO</td>
<td>Astellas Pharma Inc.</td>
<td>JPN</td>
<td>21.314</td>
<td>12.275</td>
</tr>
<tr>
<td>AZN-LN</td>
<td>AstraZeneca plc</td>
<td>GBR</td>
<td>55.133</td>
<td>17.621</td>
</tr>
<tr>
<td>BAY-FF</td>
<td>Bayer AG</td>
<td>DEU</td>
<td>90.108</td>
<td>13.231</td>
</tr>
<tr>
<td>Not publicly listed</td>
<td>Boehringer-Ingelheim</td>
<td>DEU</td>
<td>Not publicly listed</td>
<td></td>
</tr>
<tr>
<td>BMY-N</td>
<td>Bristol-Myers Squibb Co.</td>
<td>USA</td>
<td>58.248</td>
<td>9.703</td>
</tr>
<tr>
<td>4568-TO</td>
<td>Daiichi Sankyo Co. Ltd.</td>
<td>JPN</td>
<td>10.979</td>
<td>11.886</td>
</tr>
<tr>
<td>4523-TO</td>
<td>Eisai Co. Ltd.</td>
<td>JPN</td>
<td>11.819</td>
<td>8.205</td>
</tr>
<tr>
<td>LLY-N</td>
<td>Eli Lilly &amp; Co.</td>
<td>USA</td>
<td>54.332</td>
<td>18.380</td>
</tr>
<tr>
<td>GILD-O</td>
<td>Gilead Sciences</td>
<td>USA</td>
<td>59.848</td>
<td>27.987</td>
</tr>
<tr>
<td>GSK-LN</td>
<td>GlaxoSmithKline plc</td>
<td>GBR</td>
<td>108.168</td>
<td>42.119</td>
</tr>
<tr>
<td>JNJ-N</td>
<td>Johnson &amp; Johnson</td>
<td>USA</td>
<td>197.868</td>
<td>67.224</td>
</tr>
<tr>
<td>MRK-N</td>
<td>Merck &amp; Co. Inc.</td>
<td>USA</td>
<td>128.298</td>
<td>44.154</td>
</tr>
<tr>
<td>MRK-FF</td>
<td>Merck KGaA</td>
<td>DEU</td>
<td>28.216</td>
<td>14.116</td>
</tr>
<tr>
<td>NOVN-VX</td>
<td>Novartis AG</td>
<td>CHE</td>
<td>155.222</td>
<td>55.375</td>
</tr>
<tr>
<td>NOVO'B-KO</td>
<td>Novo Nordisk A/S</td>
<td>DK</td>
<td>77.479</td>
<td>50.235</td>
</tr>
<tr>
<td>PFE-N</td>
<td>Pfizer Inc.</td>
<td>USA</td>
<td>174.144</td>
<td>48.777</td>
</tr>
<tr>
<td>ROG-VX</td>
<td>Roche Holding Ltd.</td>
<td>USA</td>
<td>191.280</td>
<td>58.986</td>
</tr>
<tr>
<td>SAN-FR</td>
<td>Sanofi</td>
<td>FRA</td>
<td>128.048</td>
<td>47.347</td>
</tr>
<tr>
<td>4502-TO</td>
<td>Takeda Pharmaceutical Co.</td>
<td>JPN</td>
<td>35.886</td>
<td>19.108</td>
</tr>
</tbody>
</table>

- Company newly included in the 2014 Index scope
The 2014 Index measures 21 companies, with the addition of AbbVie since the 2012 Index. In January 2013, AbbVie split off from Abbott Laboratories to become a separate, independent biopharmaceutical company comprising Abbott’s former proprietary pharmaceutical business. Since the split-off, both AbbVie and Abbott meet the criteria for inclusion in the 2014 Index. The remaining 19 companies from the 2012 Index continued to meet these criteria and were therefore retained.

Pharmaceutical companies that exclusively produce generic medicines are still excluded from the Index in 2014. However, the Access to Medicine Foundation recognises that these companies play a significant role in access to medicine, particularly in low- and middle-income countries, and is exploring the feasibility of a separate Index for generics companies. Generic medicines marketed by the 21 research-based companies or any of their (generics) subsidiaries in which they have more than 50% ownership are included.
What we measure

Access to Medicine Index - Methodology Report 2013

Geographic Scope

The Index measures pharmaceutical companies’ efforts in countries where access to medicine is most needed based on levels of income, development and, for the first time in 2014, socio-economic equality.

The addition of the development equality criteria has resulted in the expansion of the Index geographic scope to more countries in Latin America. The 2014 Index covers 106 countries, with the addition of five new ones – Brazil, Colombia, Ecuador, South Sudan and Venezuela – and the removal of two – Algeria and Marshall Islands.

Since 2012, the Index has used the latest available World Bank country classifications as the base criteria for defining its geographic scope. This classification allows for the identification of economically disadvantaged populations at the country level and brings all low-income countries (LICs) and lower-middle income countries (LMICs) into the Index country scope. South Sudan has been added for the 2014 Index because it was newly classified as a LIC in 2013.

The level of social development in a country is also an important indicator of a population’s access to medicine. The Index uses the most recent UN Human Development Index (HDI), which aggregates important social markers of life expectancy, education and income levels per capita, to capture countries that have lower levels of development despite higher levels of income.

In recognition that widespread inequality of human development within countries often inhibits access to medicine for the poorest population segments, the Index has this year added the UN Inequality-Adjusted Human Development Index (IHDI) as a third tool for determining its geographic scope. The IHDI corrects the HDI score for inequality within a country, taking in to account such factors as the Gini coefficient of income distribution to yield a new inequality-adjusted human development score. Using the IHDI, four high human development countries (HHDC) – Brazil, Colombia, Ecuador and Venezuela – that did not fall under the World Bank LIC or LMIC classification qualified for inclusion in the 2014 Index. These countries are included regardless of their World Bank or HDI classification because they scored below 0.55 on the IHDI. This cut-off was set in order to capture countries with the greatest disparities.

Algeria is no longer covered by the Index because it is now considered a high human development country with little social inequality and the Marshall Islands are no longer covered because the World Bank now classifies it as an upper-middle-income country and because it likewise has a low level of social inequality.
Figure 3  Map of countries included in the 2014 Access to Medicine Index

- World Bank income classification
- UN Human Development Index
- UN Inequality-Adjusted Human Development Index

- 5 Countries newly included in the 2014 Index scope
- 2 Countries removed from the Index scope

Due to scaling, countries may not be visible on the map.
## List of countries included in the 2014 Access to Medicine Index – 106 countries

<table>
<thead>
<tr>
<th>Country</th>
<th>Classification</th>
<th>Country</th>
<th>Classification</th>
<th>Country</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>East Asia &amp; Pacific</strong></td>
<td></td>
<td><strong>Middle East &amp; North Africa</strong></td>
<td></td>
<td><strong>South Asia</strong></td>
<td></td>
</tr>
<tr>
<td>Cambodia</td>
<td>LIC*</td>
<td>Djibouti</td>
<td>LMIC*</td>
<td>Afghanistan</td>
<td>LIC</td>
</tr>
<tr>
<td>China</td>
<td>MHDC</td>
<td>Egypt, Arab Rep.</td>
<td>LMIC</td>
<td>Bangladesh</td>
<td>LIC*</td>
</tr>
<tr>
<td>Fiji</td>
<td>LMIC</td>
<td>Iraq</td>
<td>MHDC</td>
<td>Bhutan</td>
<td>LMIC</td>
</tr>
<tr>
<td>Indonesia</td>
<td>LMIC</td>
<td>Jordan</td>
<td>MHDC</td>
<td>India</td>
<td>LMIC</td>
</tr>
<tr>
<td>Kiribati</td>
<td>LMIC</td>
<td>Morocco</td>
<td>LMIC</td>
<td>Maldives</td>
<td>MHDC</td>
</tr>
<tr>
<td>Korea, Dem. Rep.</td>
<td>LIC</td>
<td>Syrian Arab Rep.</td>
<td>LMIC</td>
<td>Nepal</td>
<td>LIC*</td>
</tr>
<tr>
<td>Lao PDR</td>
<td>LMIC*</td>
<td>West Bank and Gaza</td>
<td>LMIC</td>
<td>Pakistan</td>
<td>LMIC</td>
</tr>
<tr>
<td>Micronesia, Fed. Sts.</td>
<td>LMIC</td>
<td>Yemen</td>
<td>LMIC</td>
<td>Sri Lanka</td>
<td>LMIC</td>
</tr>
<tr>
<td>Mongolia</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myanmar</td>
<td>LIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papua New Guinea</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Philippines</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Samoa</td>
<td>LMIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solomon Islands</td>
<td>LMIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thailand</td>
<td>MHDC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Timor-Leste</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tonga</td>
<td>MHDC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuvalu</td>
<td>LDC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vanuatu</td>
<td>LMIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vietnam</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Europe &amp; Central Asia</strong></td>
<td></td>
<td><strong>Sub-Saharan Africa</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Armenia</td>
<td>LMIC</td>
<td>Angola</td>
<td>LHDC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Georgia</td>
<td>LMIC</td>
<td>Benin</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kosovo</td>
<td>LMIC</td>
<td>Botswana</td>
<td>MHDC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kyrgyz Rep.</td>
<td>LIC</td>
<td>Burkina Faso</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moldova</td>
<td>LMIC</td>
<td>Burundi</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tajikistan</td>
<td>LIC</td>
<td>Cameroon</td>
<td>LMIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Turkmenistan</td>
<td>MHDC</td>
<td>Cape Verde</td>
<td>LMIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ukraine</td>
<td>LMIC</td>
<td>Central African Rep.</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uzbekistan</td>
<td>LMIC</td>
<td>Chad</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Latin America &amp; Caribbean</strong></td>
<td></td>
<td>Comoros</td>
<td>LIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belize</td>
<td>MHDC</td>
<td>Congo, Dem. Rep.</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bolivia</td>
<td>LMIC</td>
<td>Congo, Rep.</td>
<td>LMIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>HHIHD</td>
<td>Côte d’Ivoire</td>
<td>LMIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colombia</td>
<td>HHIHD</td>
<td>Equatorial Guinea</td>
<td>MHDC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dominican Rep.</td>
<td>MHDC</td>
<td>Eritrea</td>
<td>LIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ecuador</td>
<td>HHIHD</td>
<td>Ethiopia</td>
<td>LIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>El Salvador</td>
<td>LMIC</td>
<td>Gabon</td>
<td>MHDC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guatemala</td>
<td>LMIC</td>
<td>Gambia, The</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guyana</td>
<td>LMIC</td>
<td>Ghana</td>
<td>LMIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haiti</td>
<td>LIC*</td>
<td>Guinea</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Honduras</td>
<td>LMIC</td>
<td>Guinea-Bissau</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicaragua</td>
<td>LMIC</td>
<td>Kenya</td>
<td>LIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paraguay</td>
<td>LMIC</td>
<td>Lesotho</td>
<td>LMIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Suriname</td>
<td>MHDC</td>
<td>Liberia</td>
<td>LIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venezuela, RB</td>
<td>HHIHD</td>
<td>Madagascar</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>South Africa</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mozambique</td>
<td>LIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Namibia</td>
<td>MHDC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niger</td>
<td>LIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nigeria</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nigeria</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rwanda</td>
<td>LIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sào Tomé and Principe</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Senegal</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sierra Leone</td>
<td>LIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Somalia</td>
<td>LIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South Africa</td>
<td>MHDC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South Sudan</td>
<td>LIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sudan</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swaziland</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tanzania</td>
<td>LIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Togo</td>
<td>LIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uganda</td>
<td>LIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zambia</td>
<td>LMIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>LIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Countries removed since 2012 Index**

- Algeria (HHDC)
- Marshall Islands (UMIC)

**Notes**

- LIC: Low-income Country
  - World Bank income classification
- LMIC: Lower-middle-income Country
  - World Bank income classification
- LDC: Least Developed Country
  - UN Human Development Index
- MHDC: Medium Human Development Country
  - UN Human Development Index
- HHIHD: High Human Development Country
  - with high inequality
  - UN Inequality-Adjusted Human Development Index

* LDC with WTO membership

- 5 Countries newly included countries in the 2014 Index scope
- 2 Countries removed from the Index scope
Disease Scope

The Index measures pharmaceutical company activities that address diseases that have the greatest global burden and the greatest need in terms of access to medicine. The Index disease scope covers four main categories: communicable diseases, non-communicable diseases, neglected tropical diseases (NTDs) and maternal and neonatal health conditions.

For the 2014 Index, the disease scope has expanded from 33 to 47 conditions, largely to remain up-to-date with important epidemiological trends as reported by the World Health Organization (WHO). As in previous Indices, diseases are included based on their global burden of disability-adjusted life years (DALYs), other WHO classifications, and the relevance of pharmaceutical interventions.

Index diseases are defined according to the WHO International Classification of Diseases (ICD-10) codes. The ICD-10 identifies both primary and secondary diseases, which result from the progression of a primary disease. Primary diseases and related secondary diseases covered in the 2014 Index are listed in Appendix 2: ICD-10 Codes.

Communicable diseases
Inclusion of communicable diseases is based on disability-adjusted life years (DALYs) and relevance of pharmaceutical intervention, according to data from the 2008 update of the WHO Global Burden of Disease. The ten communicable diseases in the scope have the highest global burden of DALYs. Chlamydia is the only addition to the list of communicable diseases included in the 2014 Index, which otherwise remains the same as in the 2012 Index.

Non-communicable diseases
As with communicable diseases, the inclusion of non-communicable diseases is based on disability-adjusted life years (DALYs) according to the 2008 update of the WHO Global Burden of Disease and the relevance of pharmaceutical interventions. All non-communicable diseases from the 2012 Index remain in the scope, enabling comparability and trend analysis over time. In addition, coverage of cirrhosis of the liver has been broadened to include chronic viral hepatitis, as it can develop into cirrhosis of the liver. Two other conditions – schizophrenia and bipolar affective disorder – also have been added, in recognition of the increasing mental health burden in low- and middle-income countries according to the 2008 WHO Global Burden of Disease update and the Global Burden of Disease 2010 study. For the 2014 Index, all cancers remain excluded from the disease scope, as the disaggregated DALY burden for individual forms of cancer did not meet the criteria for inclusion (burden of 13,000 DALYs per 100,000).

Neglected tropical diseases
Neglected tropical diseases (NTDs) are considered neglected partly because the market has failed to adequately address them. They are particularly relevant in poor regions of developing countries, especially in rural areas where many cases go undiagnosed, untreated and unreported. NTDs are therefore included in the Index based on WHO disease classification from the Global Burden of Disease 2010 study rather than solely on global DALYs per disease. For the 2014 Index, the scope has been expanded to include food-borne trematodiases (which include fascioliasis), echinococcosis, rabies and cysticercosis, so that all 17 WHO-classified NTDs are now covered. Global DALYs per disease are shown where available.

Maternal and neonatal health conditions
In recognition of the importance of protecting maternal and neonatal health from conception through childbirth, the Index measures the most prevalent maternal and neonatal health conditions. The 2012 Index included a limited number of ICD-10 codes in this category; for the 2014 Index, the number of conditions covered has been significantly increased.
## What we measure

### Communicable diseases (10)

<table>
<thead>
<tr>
<th>Disease</th>
<th>Global DALYs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lower respiratory infections</td>
<td>94,511</td>
</tr>
<tr>
<td>Diarrhoeal diseases</td>
<td>72,777</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>58,513</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>34,217</td>
</tr>
<tr>
<td>Malaria</td>
<td>33,976</td>
</tr>
<tr>
<td>Measles</td>
<td>14,853</td>
</tr>
<tr>
<td>Meningitis</td>
<td>11,426</td>
</tr>
<tr>
<td>Pertussis</td>
<td>9,882</td>
</tr>
<tr>
<td>Tetanus</td>
<td>5,283</td>
</tr>
<tr>
<td>Chlamydia</td>
<td>3,748</td>
</tr>
</tbody>
</table>

### Non-communicable diseases (12)

<table>
<thead>
<tr>
<th>Disease</th>
<th>Global DALYs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unipolar depressive disorder</td>
<td>65,472</td>
</tr>
<tr>
<td>Ischaemic heart disease</td>
<td>62,587</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>46,591</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disorder [COPD]</td>
<td>30,196</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>19,705</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>16,769</td>
</tr>
<tr>
<td>Asthma</td>
<td>16,317</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>15,586</td>
</tr>
<tr>
<td>Bipolar affective disorder</td>
<td>14,425</td>
</tr>
<tr>
<td>Cirrhosis of the liver</td>
<td>13,640</td>
</tr>
<tr>
<td>Nephritis and nephrosis</td>
<td>9,057</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>7,854</td>
</tr>
</tbody>
</table>

### Neglected tropical diseases (17)

<table>
<thead>
<tr>
<th>Disease</th>
<th>Global DALYs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphatic filariasis</td>
<td>5,941</td>
</tr>
<tr>
<td>Soil transmitted helminthiasis</td>
<td>4,013</td>
</tr>
<tr>
<td>Leishmaniasis</td>
<td>1,974</td>
</tr>
<tr>
<td>Food-borne trematodiases</td>
<td>1,875</td>
</tr>
<tr>
<td>Schistosomiasis</td>
<td>1,707</td>
</tr>
<tr>
<td>Trypanosomiasis</td>
<td>1,673</td>
</tr>
<tr>
<td>Rabies</td>
<td>1,462</td>
</tr>
<tr>
<td>Trachoma</td>
<td>1,334</td>
</tr>
<tr>
<td>Dengue</td>
<td>670</td>
</tr>
<tr>
<td>Cysticercosis</td>
<td>503</td>
</tr>
<tr>
<td>Chagas disease</td>
<td>430</td>
</tr>
<tr>
<td>Onchocerciasis</td>
<td>389</td>
</tr>
<tr>
<td>Leprosy</td>
<td>194</td>
</tr>
<tr>
<td>Echinococcus</td>
<td>144</td>
</tr>
<tr>
<td>Buruli Ulcer</td>
<td>N/A</td>
</tr>
<tr>
<td>Yaws</td>
<td>N/A</td>
</tr>
<tr>
<td>Dracunculiasis</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### Maternal and neonatal health conditions (8)

<table>
<thead>
<tr>
<th>Disease</th>
<th>Global DALYs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abortion</td>
<td>7,424</td>
</tr>
<tr>
<td>Maternal sepsis</td>
<td>6,535</td>
</tr>
<tr>
<td>Maternal haemorrhage</td>
<td>4,439</td>
</tr>
<tr>
<td>Obstructed labour</td>
<td>2,882</td>
</tr>
<tr>
<td>Hypertensive disorders of pregnancy</td>
<td>1,888</td>
</tr>
<tr>
<td>Prematurity and low birth weight</td>
<td>44,307</td>
</tr>
<tr>
<td>Birth Asphyxia and birth trauma</td>
<td>41,684</td>
</tr>
<tr>
<td>Neonatal infections and other conditions</td>
<td>40,433</td>
</tr>
<tr>
<td>Contraceptive methods</td>
<td>NA</td>
</tr>
</tbody>
</table>

14 Diseases/conditions added to or expanded in the 2014 Index scope
Figure 4: DALYs of diseases in the 2014 Access to Medicine Index

What we measure

- Lower respiratory infections
- Diarrhoeal diseases
- Unipolar depressive disorder
- Ischaemic heart disease
- HIV/AIDS
- Cerebrovascular disease
- Prematurity and low birth weight
- Birth asphyxia and birth trauma
- Neonatal infections and other conditions
- Tuberculosis
- Malaria
- Chronic obstructive pulmonary disorder [COPD]
- Diabetes mellitus
- Schizophrenia
- Asthma
- Osteoarthritis
- Measles
- Bipolar affective disorder
- Cirrhosis of the liver
- Meningitis
- Pertussis
- Nephritis and nephrosis
- Epilepsy
- Abortion
- Maternal sepsis
- Lymphatic filariasis
- Tetanus
- Maternal haemorrhage
- Soil transmitted helminthiasis
- Chlamydia
- Obstructed labour
- Leishmaniasis
- Hypertensive disorders of pregnancy
- Food-borne trematodiases
- Schistosomiasis
- Trypanosomiasis
- Rabies
- Trachoma
- Dengue
- Cysticercosis
- Chagas disease
- Onchocerciasis
- Leprosy
- Echinococcosis
- Buruli Ulcer
- Yaws
- Dracunculiasis
- Contraceptive methods

DALYs total per 100,000
Product Type Scope

This scope is deliberately broad in order to capture the wide-ranging product types available to support prevention, diagnosis and treatment of relevant diseases in countries covered by the Index.

It draws heavily on the definitions provided by the G-Finder 2012 Neglected Disease Research and Development: A Five Year Review and remains unchanged from the 2012 Index. Contraceptive methods are included under maternal health conditions.

Medicines
All innovative and adaptive medicines, branded generics and generic medicines used to directly treat the target pathogen or disease process, regardless of formulation, are included. Medicines used only for symptomatic relief are not included.

Microbicides
These include topical microbicides intended to prevent HIV.

Therapeutic vaccines
This covers vaccines intended to treat infection.

Preventive vaccines
This covers vaccines intended to prevent infection.

Diagnostics
Diagnostic tests designed for use in resource-limited settings (cheaper, faster, more reliable, greater ease of use in the field) are included.

Vector control products
These include pesticides, biological control compounds and vaccines targeting animal reservoirs. Only chemical pesticides intended for global public health use and which specifically aim to inhibit and kill vectors that transmit diseases relevant to the Index are included. Likewise, only biological control interventions that specifically aim to kill or control vectors that transmit Index-relevant diseases are included. Only veterinary vaccines specifically designed to prevent animal-to-human transmission of diseases covered by the Index are included.

Platform technologies
Only those products directed specifically at meeting the needs of countries covered by the Index are included. These comprise general diagnostic platforms, adjuvants and immunomodulators, and delivery technologies and devices.
How we measure
Approach to weights and analysis

The 2014 Index uses the same framework for analysis as the 2012 Index, which enables comparison and trend analysis. The framework is constructed along seven Technical Areas, with indicators measured across four Strategic Pillars. Stakeholders have identified the Technical Areas as areas where companies have the ability to influence access to medicine.

The Index is a relative ranking, where companies are compared with each other rather than against an absolute, ideal state. The highest attainable scores for each indicator do not reflect an ideal characteristic of industry behaviour, but a culmination of stakeholder views of what can be reasonably expected of companies. Additionally, companies do not receive negative scores in indicators, meaning they can never score below zero.

The Index measures company activity in seven Technical Areas that are considered to be the most important areas to focus on for improving access to medicine in countries included in the Index. For the 2014 Index, the Technical Areas and their respective weights remain as follows:

Figure 5  How we measure

```
4 Strategic Pillars

25% Commitments  25% Transparency  40% Performance  10% Innovation

7 Technical Areas

10% General Access to Medicine Management
10% Public Policy & Market Influence
20% Research & Development
25% Pricing, Manufacturing & Distribution
15% Patents & Licencing
10% Capability Advancement in Product Development & Distribution
10% Product Donations & Philanthropic Activities
```
An in-depth overview of the Technical Areas, including a description of and rationale for the key themes is available on the following pages.

Each Technical Area is assessed along four strategic pillars: Commitments, Transparency, Performance, and Innovation. The strategic pillars are organised to capture different ‘stages’ of company performance in improving access to medicine. Commitments are the first step to actualising practice as they define what the company values and aims to achieve, for example through a code of conduct, policy, or as a signatory to international agreements. Transparency regarding policies and practices shows the company’s intent and allows it to be held accountable for its actions and values. Performance measures what companies actually do, which has the greatest impact on access to medicine, and as such, receives more weight. The final pillar, Innovation, captures how companies create or employ new and unique means to advance and lead industry practice to promote access to medicine.

### I Commitments

In this pillar, the Index measures companies’ values, strategies, policies, and codes of conduct for improving performance related to access to medicine. Companies receive more credit for commitments when they are publicly available in reports, statements, or other verifiable sources. The Index uses information collected in this pillar to track to what extent companies follow through on their commitments.

### II Transparency

In this pillar, all the indicators focus on whether the companies disclose information regarding their access to medicine initiatives. They receive credit for disclosing information, either publicly or to the Index through one-on-one engagement, regardless of whether the content has a positive impact on access to medicine. This is to encourage companies to be transparent and accountable regarding their policies and activities. Public transparency is given more weight because it promotes accountability to a wider audience.

### III Performance

This pillar focuses on what companies are actually doing to promote access to medicine through the implementation of initiatives within the seven Technical Areas. It shows where companies put policies and priorities into action to achieve what they committed to do. Because these actions can have the most meaningful impact on access to medicine, this pillar receives the most weight.

### IV Innovation

As the pharmaceutical industry as a whole looks for ways to enter new markets and address current industry challenges, companies can develop innovative strategies and models that make access to medicine more sustainable. In this pillar, the Index measures what companies do to shape their core competencies to improve access to medicine. It identifies the industry as an important driver of change, recognising that it acts within an environment where multiple actors may influence the access to medicine landscape.
A General Access to Medicine Management

This Technical Area focuses on the integration of access to medicine issues into a company’s core strategies, governance structures and management systems. The Index seeks to understand the strategic reasoning behind companies’ access to medicine initiatives, as they tend to be most effective and sustainable when developed as part of a clear corporate strategy and supported by a strong rationale. This Technical Area also analyses the company’s stakeholder engagement in relation to access to medicine issues, to assess to what extent companies consider stakeholder needs, conditions and perspectives.

Managing for access to medicine outcomes
Assigning responsibility and accountability for access to medicine to the board ensures it is integrated into a company’s corporate strategy. Clearly formulated quantitative and qualitative time-bound targets that are supported by performance management systems, and incentives to reward activities that promote access to medicine, can improve implementation and assessment.

Stakeholder engagement
Pro-active stakeholder engagement allows for constructive dialogue and knowledge sharing around access to medicine initiatives. Engaging with local stakeholders is particularly useful when tailoring access to medicine strategies to local conditions and needs. Paying attention to stakeholder views can enable companies to address relevant issues and incorporate perspectives.

Access to medicine strategy
Short-, medium- and long-term goals and targets are an important part of company strategies as they drive actions that improve access to medicine. A clear access to medicine strategy that is supported by a strong rationale can contribute to systematic, long-term access to medicine. Public visibility and transparency of companies’ access to medicine policies, practices and outcomes enable stakeholders to hold companies accountable.

Innovation in business models
Innovative business models that address the needs of the poor can benefit patients as well as provide economic value for both society and the company.

2014
The analysis of company access to medicine strategies will be broadened in the 2014 Index to include an assessment of the extent to which companies tailor them to local needs, conditions and expectations. Measurements of innovation in this area will focus on business models that are both economically viable for the company and beneficial for access to medicine.
B Public Policy & Market Influence

This Technical Area seeks to capture how companies deal with matters of business ethics that can influence access to medicine. The measures companies take to gain access to and penetrate markets and/or improve access to medicine can affect competition, prices and supply of medicine. These measures include engagement with policymakers and other stakeholders to influence policies and markets in ways that can affect patients' access to medicine, as well as the many political, regulatory and marketing processes companies employ to represent their interests.

Lobbying
Disclosure of policies and activities regarding political and/or financial contributions and lobbying for company interests helps to determine potential conflicts of interest that can inhibit access to medicine. It also allows companies to be held publicly accountable for their actions in this area. Lobbying for additional measures to protect intellectual property in trade agreements is also included in this Technical Area, as this type of lobbying can have a market-wide influence.

Competitive behaviour
Competition between pharmaceutical companies can lead to improvements in affordability and access to medicine. Activities that can limit competition include entering into arrangements with generics manufacturers to delay their market entry, price collusion, or the use of data exclusivity laws. Waiving data exclusivity when there is a need for medicine can accelerate the market entry of products from competitor manufacturers.

Ethical marketing
Enforcing strong ethical marketing policies and practices can promote access to medicine by encouraging safe and rational use of medicine. Effective management of such codes, including monitoring and auditing of marketing and promotional programmes, improves adherence. Disclosure of marketing activities such as payments to healthcare professionals and key opinion leaders related to marketing practices increases the ability of the public – and especially patients – to determine where potential conflicts of interest or unwanted influence on the market may exist.

Anti-corruption and anti-bribery
Corrupt practices can affect patient safety and health, divert valuable resources from public health needs and erode confidence in companies. Strong anti-corruption and anti-bribery codes of conduct and enforcement of such codes internally and with external parties enhances public accountability.

Innovation in public policy and market influence
Innovative means of establishing and promoting ethical business practices in areas such as lobbying, pro-competitive practices, marketing, and anti-corruption and anti-bribery can support access to medicine. Innovative ways of advocating for improved access to medicine in developing countries without a conflict of interest and without losing profitability can foster sustainable solutions in this area.

The 2014 Index will include company breaches of codes of conduct or laws surrounding ethical marketing, lobbying, corruption, bribery or anti-competitive behaviour that occur not only in countries covered by the Index, but now anywhere in the world. This is because breaches occurring outside the Index geographic scope can affect access to medicine in countries covered by the Index, but may not be reported or settled through formal public channels within these countries.
C Research & Development

This Technical Area analyses in-house and collaborative research aimed at developing new or adapted products for high-burden diseases. The development of these products represents an important step in making them available for people in countries included in the Index and is therefore a crucial factor in improving access to medicine. This Technical Area also seeks to capture company policies and behaviour that influence access to medicine within the R&D processes. This covers clinical trial conduct, the provision of post-trial access to medicine, compliance with globally accepted standards and data transparency.

Product development

Product development refers to the creation of new drugs, vaccines and diagnostics that were previously unavailable or ineffective, as well as to the adaptation of existing products to suit conditions in the countries covered by the Index. Aligning the development of new and adapted products with international priorities and local needs can lead to the creation of novel and improved products. Additionally, new and adapted platform technologies can greatly improve the quality, delivery and efficacy of such medicine, and sharing such technologies with research partners can enable more and faster product development.

Collaborations and knowledge sharing

Engaging in collaborative R&D partnerships in any phase of product development enables resource sharing and mitigates risk, which can bring products to the market and patients more quickly. Sharing of intellectual property, knowhow, expertise, compounds, resources, processes and technologies can facilitate more efficient product discovery and development. The terms and conditions of partnerships can greatly affect the rate at which and terms under which products can be developed, and the disclosure of these terms allows parties involved to be held more accountable.

Clinical trial conduct, data transparency and post-trial access to medicine

Conducting ethical clinical trials, whether in-house or outsourced to third parties, facilitates appropriate treatment of patients and increased confidence in products. Compliance with internationally accepted standards such as Good Clinical Practice (GCP) and the Declaration of Helsinki for both in-house and outsourced clinical trials can ensure ethical conduct towards trial participants, enhances the quality of data and improves patient safety. Effective management of clinical trial procedures through regular monitoring and auditing encourages compliance with codes of conduct, reducing the risk of breaches and harmful consequences. Sharing all data from trials conducted in countries included in the Index, regardless of outcome and whether run in-house or through a third-party, enhances research potential while limiting the need for additional investments. Publication of these data also increases the accountability of those who conduct clinical trials and allows healthcare providers, academics and patients to engage with them for further research and discussion. When products are developed in countries included in the Index geographic scope, providing patients with post-trial access to these products improves medicine availability.

Innovative R&D models

Innovative R&D models that target current gaps and issues in product and technology development can lead to improvements in the rate, quality and quantity of medicine that emerges from R&D pipelines.
D Pricing, Manufacturing & Distribution

This Technical area centres on how companies attempt to make products affordable and on the efficiency with which products are produced and distributed. Access to medicine is restricted if products are priced above what patients are able to pay. In addition to multiple factors that influence a product’s price, both the prices set by pharmaceutical companies and the mark-ups added along the supply chain can significantly influence product affordability. Along with effective price-setting strategies, brochure and packaging adaptation, product registration and timely filing for market approval can limit problems throughout the supply chain and improve access to medicine.

The 2014 Index will measure all equitable pricing strategies, instead of only tiered pricing programmes, as was measured in the 2012 Index. In addition, it will assess how companies design, implement and monitor pricing schemes designed to maximise affordability by examining disclosure of volume of sales and price points intended for poor population segments.

Equitable pricing strategies
Pricing medicine in a way that addresses local needs can improve access to medicine for poorer population segments within the index’s geographic scope. Such pricing strategies can include tiered pricing schemes that differentiate product prices both between and within countries, and other equitable pricing schemes, typically based on socio-economic factors.

Accountability for sales agents’ pricing practices
Mark-ups can significantly increase the price patients pay for medicine. Monitoring and auditing pricing practices of sales agents wherever possible can improve access to affordable medicine.

Brochure & packaging adaptation
Tailoring product and packaging attributes enhances the ability of patients to gain access to products and use them in the most effective way, and thereby facilitates rational use. This includes adapting brochures and packaging to local circumstances such as literacy levels, languages, cultural considerations and environmental conditions. Distinct packaging, branding and other types of adaptation also help limit diversion of differentially priced products between population segments.

Product registration and filing for marketing approval
For eligible, relevant and necessary products, applying for WHO Prequalification; seeking tentative approval from the US Food and Drug Administration, European Medicines Agency or other stringent regulatory authorities; and wide and rapid registration and filing for marketing approval are important steps that can facilitate timely access to products.

Drug recall policies & practices
When carried out effectively according to the global standards prescribed by WHO, product recalls can ensure that unsafe products are removed from the market as efficiently as possible. Public disclosure of recalls can enable patients who have obtained such medicine prior to the recall to gain access to the necessary care to limit the negative impact of recalled drugs.

Innovation in equitable pricing, manufacturing and distribution
Innovative equitable pricing and affordability models, including financing mechanisms, can promote sustained delivery of affordable products. In addition, innovation that addresses manufacturing and distribution issues can minimise costs, maximise efficiency and facilitate adequate supply of quality medicine.
This Technical Area focuses on companies’ intellectual property protection strategies and practices, including those pertaining to the rights of countries to utilise Trade-Related Aspects of Intellectual Property Rights (TRIPS) flexibilities outlined in The Doha Declaration\(^{13}\), and the possible impact of these practices on access to medicine. Engaging in pro-active intellectual property strategies for diseases included in the Index can make medicine more affordable and accessible.

### Intellectual property strategy
Allowing or enabling competition from generics manufacturers can improve affordability of quality medicine in countries covered by the Index. Research-based companies can facilitate such competition by refraining from patenting or enforcing patents in a manner that negatively affects access to medicine in countries with the greatest need. They can also do so by issuing access-oriented non-exclusive voluntary licences or non-assert declarations, engaging in innovative patent pooling ventures, and engaging in public health-oriented technology transfer and licencing agreements. Disclosure of patent filings and the terms and conditions of licences enables manufacturing parties to, for example, better navigate licencing negotiations.

### Intellectual property aspects of trade
Transparency surrounding a company’s position regarding the TRIPS agreement and the use of TRIPS flexibilities demonstrates its consideration of intellectual property challenges that affect access to medicine and allows a company to be held publicly accountable for its stance. By refraining from practices that challenge the TRIPS agreement or that challenge a country’s use of TRIPS flexibilities, or by implementing licencing terms that support countries’ rights in this area, companies can show their support of the TRIPS agreement and the rights to use TRIPS flexibilities.

### Innovation in intellectual property strategies
Development and implementation of innovative models of intellectual property management can increase competition and the supply of medicine.
F Capability Advancement

This Technical Area focuses on the long-term, systemic engagement of companies with local stakeholders to strengthen local capacity to improve quality and accessibility of medicine. This includes activities related to research, development, production and distribution of medicine, as well as the local monitoring of product safety once it is on the market. Such activities can be implemented through partnerships and collaborations with local actors, and by contributing and/or transferring skills and expertise in areas where a need exists.

The 2014 Index will place more emphasis on capability advancement initiatives that are aligned with local needs, including collaborations to strengthen the capacity and expertise of staff involved in supply chains and R&D.

Capacity building in Quality Management Systems and manufacturing standards
Access to medicine in countries covered by the Index can be improved through sustainable local production of quality medicine. Local capacity in manufacturing can be improved by training local in-house and third-party manufacturers to comply with globally accepted standards such as the WHO Good Manufacturing Practices (GMP)14 or equivalent international/internal quality standards. It can also be improved by adequate technology transfer, and by implementing efficient Quality Management Systems (QMS). Including stringent international quality standards in contracts with local manufacturers can help to ensure that locally manufactured products are of sufficient quality, promoting increased access to safe and effective medicine.

Capacity building in R&D
Partnerships and collaborations with public sector research organisations and/or academic institutions in countries that the Index covers can contribute to the growth of local clinical trial and product development capacity. Such initiatives can also include training the necessary clinical, scientific or technical researchers and managers to administer these processes locally.

Capacity building in supply chain management
Efficient supply chains are needed to ensure quality products reach the people who need them. Strengthening locally appropriate supply chain capabilities can reduce product diversion, deterioration, stock-outs and counterfeiting. Additionally, a strong local supply chain can prevent information gaps, which improves overall forecasting and procurement management.

Capacity building in pharmacovigilance
Pharmacovigilance systems are an important driver of product quality and safety once medicine is on the market. Companies can contribute to strengthening national and regional pharmacovigilance systems by collaborating with local institutions to build pharmacovigilance capacity. This includes providing post-marketing surveillance data to governments to help them build strong central information repositories in line with national or regional plans.

Initiatives to build other capacities
Additional on-the-ground initiatives outside of the pharmaceutical value chain can help make products more accessible to patients, provided conflict of interest is fully absent. This may include collaborating with or contributing to initiatives run by reputable international organisations that are working with local stakeholders.

Innovation in local capability advancement
Innovative approaches to improving local capabilities in quality and supply chain management are important for improving product affordability, quality and overall access to medicine. Innovative ideas can focus on securing the pharmaceutical supply chain, demand forecasting, pharmacovigilance, and local quality management, as well as R&D and product development capacities.
G Product Donations & Philanthropic Activities

This Technical Area assesses how companies implement the donation of products aimed at controlling, eliminating and eradicating diseases affecting those most in need. It also focuses on philanthropic activities that bring financial assistance to people and organisations in the countries within the Index geographic scope. Successfully implemented product donations and philanthropic activities that are based on a clear underlying strategy can significantly contribute to improved health outcomes for those most in need.

Product donations
Single- or multi-drug donations carried out in emergency situations or as part of a control, elimination or eradication programme can greatly decrease the burden and spread of disease among those who would not otherwise have any access to the necessary products. Product donations tend to be most effective when they are carried out in accordance with a sustainable strategy, supported by adequate supply and commitment, and aligned with local needs and priorities. Guidelines such as the WHO Guidelines for Medicine Donations [5] and the Partnership for Quality Medical Donations (PQMD) Principles and Standards [6] outline good manufacturing practices, criteria for suitable products and monitoring and evaluation standards for effective product donations. Following these globally accepted guidelines promotes access to safe, suitable products and improves the efficiency of product delivery to the intended recipients. Additionally, coordination and collaboration with national governments, NGOs, WHO and/or local organisations can ensure appropriate donations strategies and lead to successful delivery outcomes. Continual outcome reporting and health impact assessments can also assist in determining whether donations are implemented appropriately to address health needs.

Sustainable philanthropy
Financial support of local people and organisations can significantly enhance countries’ local capacities. Investment in activities that align with global health priorities, with a clearly defined strategy, can improve local healthcare infrastructure and have a long-term positive impact on access to medicine. Monitoring and impact assessment are important for determining the effectiveness of activities in a company’s philanthropic portfolio.

Innovation in donations and philanthropy
Innovative approaches to product donations and philanthropic activities can improve efficiency and increase the impact of programmes, enabling them to better address local challenges. Using innovative approaches to scale up product donations can allow such programmes to reach even more people in need. Methods to improve local healthcare infrastructure and facilitate better patient outcomes can help to reduce the need for long-term donations and philanthropic activities.

In the 2014 Index, this Technical Area will place more emphasis on strategic and integrated approaches towards product donations and philanthropic activities, including needs-based initiatives and impact assessments that determine effectiveness.
Refining the methodology
Refining the Methodology

The Access to Medicine Index is a product of a two-year process known as the ‘Index cycle’. During year one of the cycle, the Foundation focuses on reviewing and revising the Index methodology based on expert stakeholder feedback. Year two is spent collecting and analysing pharmaceutical company data according to the latest Index methodology, with the help of an independent research partner. The results are then published in a new Access to Medicine Index, and the cycle begins again.

In 2013, the Foundation conducted a thorough review and extensive consultations to ensure that the 2014 Index reflects evolving access to medicine priorities while maintaining consistency with previous Index iterations for the purposes of comparison and trend analysis.

Internal and external review

The Index team began by conducting an extensive quantitative and qualitative analysis of the methodology and data from past indices, including:

- **Statistical analysis** to determine quality and robustness of indicators and related questions used to gather data. The analysis, the rigour of which was stepped up for the 2014 Index, used correlation matrices, response rate analysis and examination of the distribution of company performance per indicator and clusters of indicators. Moreover, the Index team analysed the most predictive and discriminatory indicators, highlighting those to be retained for longitudinal trend analysis and key areas for methodological improvement.

- **Qualitative analysis** of the indicators, analysing all data received and company response level to specific indicator questions. The relevance of these indicators to the access to medicine landscape was assessed through a literature review as well as through stakeholder consultations (see Appendix 1 for an overview of stakeholder engagement). The companies, countries, diseases and product types included in the Index were (re)evaluated using the latest relevant data (see What we measure).

In addition to the internal analysis, external feedback was collected from experts, stakeholders and the public through various channels, including a public online survey, calls with companies ranked in the 2012 Index and various stakeholder meetings (See Appendix 1 for more detail). This external feedback was incorporated into both the qualitative and quantitative aspects of the review process as well as subsequent consultations with the Technical Subcommittees (TSCs) and the Expert Review Committee (ERC).
Expert committee consultations

The Foundation follows a formal process of consultation with committees that provide strategic guidance, technical expertise and insight on stakeholder perspectives to contribute to the Index methodology. Technical experts were convened as Technical Subcommittees (TSCs) to give input per Technical Area. The Expert Review Committee (ERC), comprising experts from various stakeholder groups, provided strategic guidance for the overall methodology and approved the finalised methodology for the 2014 Index in September 2013.

The Foundation shared its proposals regarding the 2014 Index methodology with the members of each committee during a series of separate meetings. Each committee responded to these proposals with recommendations, many of which were subsequently incorporated into the 2014 Index methodology. For more detail on these committees’ roles in the methodology development process, refer to Appendix 1 (p. 55).

Considerations and outcomes

Using the results of the internal indicator analysis, external feedback and committee consultations, the Index team refined the indicators in the 2012 Index to arrive at a new set of 95 indicators for the 2014 Index. These indicators are listed starting on p. 37. Throughout the methodology review and development process, several key themes for discussion emerged. The considerations and outcomes of some of these noteworthy discussion topics are highlighted below.

More meaningful measures of affordability

The 2012 Index indicated that more companies are using tiered pricing schemes and applying them to a broader range of products and in more countries. However, the size of the price differential between markets and the proportion of products covered in different countries were not ideal indicators, as the price offered to the lowest population segments could still be unaffordable. The internal review suggested that the focus of analysis should be shifted towards affordability rather than comparison of pricing programmes.

However, evaluating the affordability of pharmaceutical products presents a formidable challenge, as there is no consensus on standards, definitions or reference prices. This issue was discussed both in the Technical Subcommittee and Expert Review Committee, and feedback was also collected from many other experts. This topic was also debated at the Strategic Access to Medicine Workshop and the Foundation’s stakeholder dialogue in Ghana in an attempt to identify more meaningful key performance indicators of affordability.

All stakeholders consulted agreed that affordability can be defined as the end user’s ability to pay for products, and that a true measure of medicine affordability is only possible with a universally accepted reference price for each product. Participants at the Ghana meeting recognised that ensuring affordability is difficult for multiple reasons, with solutions requiring the involvement of multiple stakeholders. It was agreed that companies continue to play an important role, as they can set prices and develop equitable pricing initiatives based on strategies that – ideally – meet the needs of local communities and reflect the local context. Participants recognised these strategies are not easy to implement, as one size does not fit all products, diseases, geographic areas or healthcare systems.

As a result of the internal review and external consultations, it was agreed that volume of product sales to segments of populations can be useful as a measure of affordability, as it can help to capture the degree of price reduction and the extent to which a treatment is available in the poorest markets. However, factors such as therapeutic area and market size should be taken into account when doing so, as there are also cases for which sales volume is not meaningful (e.g. for treatment of secondary diseases).

With the diversity of diseases covered in the portfolio of marketed products and the variations within countries where companies are active, using a measure of price point of all prod-
ucts as a way to compare affordability of products is considered impossible at this point. The proposed direction for the 2014 Index methodology was to assess the strategy behind price decisions made by companies, including any internal measures of affordability such as uptake of products within different population segments. It was also concluded that volume of sales in countries covered by the Index should be tested as a potential measure of affordability.

The Index team piloted proposed measurements of pricing strategies with companies included in the Index to assess their feasibility. Of the 21 companies invited, eleven provided feedback about the level and type of data they could provide. Their input led to adjustments of the final indicators and corresponding data collection points.

As a result of this in-depth review, the 2014 Index methodology measures the rationale behind companies’ equitable pricing strategies that aim to make products affordable for the poorest population segments. Analysis of equitable pricing schemes now includes disclosure of volume of sales to the poorest segments. This shift in focus eliminated the assessment of tiered pricing differentials. The Index will now capture all forms of equitable pricing strategies where companies include socio-economic needs and affordability in determining commercial pricing for diseases in the Index geographic scope.

**R&D based on a public health need**

The 2012 Index found that many companies have increased investment in relevant R&D in diseases covered by the Index, often through increased collaboration and knowledge sharing. R&D pipelines are thus addressing the need for more and better products in countries in the Index geographic scope. However, R&D continues to be important to monitor as there is still room for improvement in the availability of effective medicine for treating, preventing or diagnosing many diseases in countries covered by the Index.

The Index team’s internal analysis and discussions regarding R&D yielded two main topics for further examination: the extent to which companies are addressing unmet needs in countries covered by the Index in their R&D portfolios, and clinical trial conduct in countries covered by the Index. The needs met by R&D pipelines could ideally be measured against an internationally agreed upon priority R&D agenda such as the WHO Priority Medicines Report17, but such a standard is not currently available for all diseases and geographic regions. Moreover there is a lack of consensus regarding priorities in many areas of R&D. The 2014 Index will assess how companies’ R&D pipeline (potentially) addresses public health needs. Best practices for collaboration were also discussed to differentiate between efforts that are truly collaborative and those that are not.

The second issue identified as a result of the Index team’s internal analysis underwent a separate round of discussions with various experts and stakeholder group representatives, including the TSC and the ERC. The 2012 Index noted that while many companies have followed the internationally accepted guidelines for clinical trials11,12, there was still a need for more stringent auditing and enforcement of clinical trial codes of conduct in the countries included in the Index. The importance of clinical trial data availability and ethical considerations for clinical trials conducted in countries covered by the Index were emphasised during these discussions and consequently given more attention in the 2014 Index methodology. The issue of post-trial access to medicine also continues to be important in the 2014 Index methodology, as sharing best practices in this area can increase access to people living in countries where clinical trials have been conducted.

**Capturing (un)ethical company behaviour, wherever it occurs**

The 2012 Index found that companies show more commitment to public accountability, stakeholder engagement and high standards of business ethics. However, recent allegations of bribery and corruption in China have highlighted the need for better management and enforcement of ethical business practices and public accountability. Companies can support policies and markets in a manner that promotes access to medicine, particularly by sharing
best ethical business practices in anti-corruption, anti-bribery and ethical marketing in countries where the regulations and enforcement may be weak or lacking. The 2014 Index methodology therefore places greater emphasis on companies’ monitoring and auditing of ethical business practices.

The underlying issue in this area is the lack of public information available to assess company behaviour, as market influence often occurs through informal channels and can take place everywhere in the world. Many experts and stakeholders offered their input on how to capture lobbying and/or breaches, regardless of where they occur. As a result, the scope of relevant breaches has been expanded to include settlements, court cases, and fines that occur anywhere in the world, rather than solely in countries included in the Index.

The discussion with the TSC focused on differentiating between company behaviour that complies with the law and behaviour that is either favourable or unfavourable toward access to medicine in the Index geographic scope. Given the importance of capturing the effect of companies’ practices on access to medicine, indicators in this Technical Area now include both legal and referenced definitions of terms related to Public Policy and Market Influence.

**Reflecting a changing industry in the IP landscape**

Since the publication of the 2012 Index, there have been important developments in the intellectual property landscape, such as the extension of the TRIPS implementation period for Least Developed Countries (LDCs). Additionally, one of the biggest drivers of change in the pharmaceutical industry is the development of patent systems in emerging markets—Brazil and South Africa most notably—which, like India previously, are reshaping to be more enabling of generic competition.

In the past years, research-based companies have made more acquisitions, joint-ventures and licencing deals with local generic manufacturers, giving companies an opportunity to tap into emerging markets while recouping R&D costs and thus improving access to medicine for people living in developing countries. Since these alliances can facilitate more efficiency in production and distribution, the stakeholders and TSCs involved in discussions on this topic felt that the 2014 Index should emphasise the importance of technology transfer and socially responsible licencing (SRL). The 2014 Index methodology now includes an indicator that investigates how the terms and conditions of licences support access to medicine in countries covered by the Index.

TSCs also felt that enabling the manufacture and distribution of affordable drugs in the countries covered by the Index could be facilitated by refraining from filing or enforcing patents not only in LDCs represented in the WTO but also in all Low-Income Countries (LICs) and Lower-Middle Income Countries (LMICs). The scope of countries examined in indicators relevant to patent filing and enforcement has thus been updated accordingly in the 2014 Index methodology.

**Expanding the scope of the Index**

When considering any change in scope, the Index team takes a methodological approach. It received considerable feedback from its online survey on the need to increase the scope of the Index to include more companies - including generics manufacturers – and more diseases, including mental health conditions, cancers and hepatitis. Both the Index team and external stakeholders also recognised the need to address disparity within countries and include higher-income countries that have a large number of people living in poverty.

The company scope for the 2014 Index was only changed to reflect splits, mergers or a change in the relevance of companies’ products to the disease scope. It was proposed that the Index could encourage companies that have no operations in countries in the Index geographic scope to start doing so if they have relevant products in their portfolio. Such companies may be considered for assessment in future iterations of the Index.
Countries in the Index geographic scope were assessed using three selection criteria: World Bank classification, the UN Human Development Index and the UN Inequality-Adjusted Human Development Index (IHDI). Discussions regarding the addition of IHDI criteria led to a unanimous ERC recommendation to include four new countries with a wide disparity of human development: Brazil, Columbia, Ecuador and Venezuela. Future iterations of the Index could see more countries included based on this set of criteria.

Since the majority of medicines in countries covered by the Index, including the majority of those in the most recent WHO essential medicines list, are generics, the Index methodology continues to capture products sold by generics subsidiaries of research-based companies, and may embark on an Index solely for generics companies in the future.

The past years have seen roadmaps and calls to action to control, eradicate and eliminate priority diseases. Notable are the London Declaration in 2012, which has led to many global stakeholders stepping up efforts to address neglected tropical diseases; the WHO NCD Action Plan 2013-2020 and Sixty-Sixth World Health Assembly’s Comprehensive Mental Health Action Plan for 2013-2020 which aims for better policies and practices in these areas in the coming years; and the Millennium Development Goals and post-2015 priority setting discussions for the next round of MDGs, which include collaboration, data availability and improvements in maternal and child health. The 2012 Index found that companies are moving towards more targeted needs-based programmes to align with such calls in areas such as drug donations. To continue to encourage companies to address priority diseases in alignment with such multi-lateral movements, the 2014 Index methodology includes diseases based on their global burden, according to the latest WHO data. As a result, two mental health conditions (schizophrenia and bipolar affective disorder) and hepatitis (as part of liver cirrhosis) were added to the scope. Although the aggregate global burden of cancer is high, it is not included in this year’s methodology because individual forms of cancer – often requiring specialised diagnostics and treatments – do not have a high enough disease burden to be included in the 2014 Index methodology.

**Changes in depth and breadth to better measure progress**

The role of pharmaceutical companies in addressing the issue of access to medicine is complex and multifaceted. By measuring interlinked aspects of company behaviour in seven Technical Areas, the Index seeks to capture changes in areas where companies can meaningfully contribute to the advance of access to medicine. The 2014 Index methodology as a whole has been adjusted to address a complex, evolving landscape and several strategic changes have been made.

The 2012 Index showed that companies’ approach to access to medicine is more organised and that products and pipelines are meeting more needs and that the pharmaceutical industry as a whole is gradually progressing in all areas. What remains to be seen is how the increasing number and scope of company initiatives will affect access to medicine in the countries included in the Index, but this impact measurement falls outside the Index’s current framework of analysis. The 2014 Index can, however, place greater emphasis on how companies create and manage their access to medicine strategies in alignment with local needs and priorities, as well as how companies measure the outcomes of their programmes and, in turn, use these measurements to update their access strategies.

The 2014 Index methodology thus focuses on how local stakeholders and priorities inform and shape company strategies and the alignment of these strategies to global, regional, national and local priorities. The 2012 Index findings suggest that strategies that include this continuous feedback loop are already being developed and implemented within several companies, as reflected in the growth of stakeholder engagement, leadership and innovation of policies and processes in certain key areas.
To effectively measure company progress, the changing pharmaceutical industry landscape and blurring lines between generics and research-based companies must be reflected in the Index methodology. The 2014 Index methodology places more emphasis on the need for access to medicine in countries covered by the Index to become an integral part of ‘business-as-usual’ within companies. As a result, the revised methodology seeks to capture how well companies maintain profitability while fostering adequate access to medicine in the countries covered by the Index, thus facilitating sustainability in terms of health and economic benefits for local health systems as well as economic benefits for pharmaceutical companies and associated shareholders. This is evident in the ways in which indicators have been adjusted throughout most of the Technical Areas, including the decision to shift the focus of the Innovation pillar within General Access to Medicine Management Technical Area to business model innovation.

A lack of consensus on definitions and standards in many areas can make it difficult to find a clear, reasonable definition of a pharmaceutical company’s role. In order to accommodate this in the Index framework, the 2014 Index methodology includes updated definitions, using both universally accepted definitions and working definitions to cover terms used when measuring and analysing access to medicine. Definitions used in the 2014 Index are listed in Appendix 3: References, Definitions & Acronyms (p. 65).
Indicators

Indicator-level changes
A list of all 95 indicators that will be used to assess companies in the 2014 Access to Medicine Index is available in the following pages. Indicators were retained, changed or deleted based on the following guidelines:

Indicators were retained when:
• The specific data available was of sufficient quality;
• They remained relevant to access to medicine; and
• In some cases, when they were usable for longitudinal analysis.

Indicators were considered for change when:
• Average company scores were unevenly high or low, as compared to actual high or low activity in companies, signifying opportunities to increase the standard or address low scores by enhancing indicators;
• Their relevance to access to medicine had changed; or
• They could be combined with other indicators to simplify the data collection.
A General Access to Medicine Management

2014 Indicator | Change/ rationale
--- | ---

A.1 Commitments - 25%

A.I.1 Governance: management structures
The company has a governance system that includes direct board-level responsibility and accountability for its access to medicine initiatives for Index Countries.

A.I.2 Stakeholder engagement
The company commits to work with relevant stakeholders, including universities, patient groups, local governments, employees, local and international NGOs and peers with the aim of improving access to medicine.

A.II Transparency - 25%

A.II.1 Strategy: policies & practices
The company reports on its access to medicine strategy and discloses its overall rationale for its access to medicine activities.

A.II.2 Strategy: policies & practices
The company discloses goals and targets (both qualitative and quantitative) and performance measures for its access to medicine practices related to the Index Countries.

Minor Change
More focus on access to medicine strategy.

Minor Change
Clarification of wording.

A.III Performance - 40%

A.III.1 Governance: management structures, performance management & incentives
The company has a performance management system including quantitative targets to implement and monitor its access to medicine strategy in the Index Countries.

A.III.2 Stakeholder engagement
Senior management participates in public debate and engages with different stakeholder groups with the goal of dialogue and knowledge sharing aimed at improved access to products for the Index Diseases in the Index Countries (the company organises/facilitates/hosts relevant conferences, symposia, workshops etc. attended by senior management).

Minor Change
Clarification of wording.

A.III.3 Governance: performance management & incentives
The company has internal incentive structures to reward effective delivery of initiatives that improve access to medicine in the Index Countries for the Index Diseases.
<table>
<thead>
<tr>
<th>2014 Indicator</th>
<th>Change/ rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A.III.4  Strategies, stakeholder engagement</strong>&lt;br&gt;The company has a system in place to incorporate external and local (market) perspectives on access to medicine needs in the development and implementation of access strategies.</td>
<td>New 2014&lt;br&gt;To capture needs-based access to medicine strategy based on local perspectives (Piloted).</td>
</tr>
</tbody>
</table>

| **A.IV  Innovation - 10%**<br>**A.IV.1  Innovation in general access to medicine management**<br>The company has contributed to the development of innovative business models that meet the needs of patients in Index Countries. | Major Change<br>To capture business model innovation that is economically viable and beneficial for access to medicine. |

*Note: unless otherwise specified, indicator has remained the same as in the 2012 Index*
## Public Policy & Market Influence

### B.1 Commitments - 25%

#### B.1.1 Endorsement of competition
The company commits to endorse and support competition and to refrain from anti-competitive practices or pursue arrangements with generics that might delay their market entry in the pharmaceutical markets in the Index Countries for products related to the Index Diseases.

#### B.1.2 Non-pursuit of data exclusivity
The company’s policies and practices surrounding data exclusivity do not impede access for products related to the Index Diseases in the Index Countries.

**Minor Change**
To emphasise the utilisation or waiver of data exclusivity laws, which can impede or promote access.

#### B.1.3 Ethical marketing
The company commits to enforce a code of conduct regarding ethical marketing practices for all sales agents and local third party distributors and contractors consistent with its own internal standards and any existing industry standards.

**Minor Change**
Clarification of wording to highlight the importance of maintaining ethical marketing standards that are at minimum cohesive internally with industry standards.

#### B.1.4 Anti-bribery/anti-corruption
The company commits to proactively engage in fighting corruption through its internal anti-bribery and anti-corruption codes of conduct, external commitments and memberships.

### B.2 Transparency - 25%

#### B.2.1 Lobbying
The company is transparent about its lobbying positions, political contributions and positions it seeks to promote where it has an impact on access to medicine in Index Countries, either directly or indirectly.

**Minor Change**
Clarification of wording to increase standards and emphasise transparency beyond company policy.

#### B.2.2 Influence
The company discloses membership and financial support of trade associations, think tanks, interest groups, or other organisations, including any potential governance conflict of interests, through which it might advocate its public policy positions at regional, national or international levels where relevant to access to medicine in the Index Countries.

**Minor Change**
Clarification of wording to specify the groups or institutions of interest.

#### B.2.3 Influence
The company discloses its board seats at industry associations and advisory bodies related to health access issues for the Index Diseases and the Index Countries.
## 2014 Indicator

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Change/ rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>B.II.4 Endorsement of competition</strong></td>
<td>The company discloses policies related to competition in areas such as data exclusivity, patent extensions or other arrangements with generic companies that might delay their market entry for Index products in the Index Countries.</td>
</tr>
<tr>
<td><strong>B.II.5 Ethical marketing</strong></td>
<td>The company publicly discloses detailed information regarding its marketing and promotional programmes in the Index Countries, such as payments to or promotional activities directed at physicians or other key healthcare professionals or opinion leaders. Minor Change Clarification of wording to emphasise the importance of public disclosure.</td>
</tr>
<tr>
<td><strong>B.II.6 Ethical marketing, anti-bribery/ anti-corruption</strong></td>
<td>The company voluntarily discloses all information regarding its breaches of internal and internationally recognised codes of conduct for ethical marketing, lobbying, bribery and/or corruption in any country in the last two years, including litigations related to marketing practices in the Index Countries. Minor Change From five years to two years to avoid overlap of data collection and analysis between Indexes. Scope of countries expanded.</td>
</tr>
<tr>
<td><strong>B.III Performance - 40%</strong></td>
<td></td>
</tr>
<tr>
<td><strong>B.III.1 Lobbying, ethical marketing, anti-bribery/ anti-corruption</strong></td>
<td>The company has been in breach of any national or international codes of conduct in any country in relation to lobbying, ethical marketing and/or bribery and corruption. Minor Change Scope of countries expanded.</td>
</tr>
</tbody>
</table>
| **B.III.2 Endorsement of competition**                                   | There is evidence* of the company’s anti-competitive behaviour** that impacts access to medicine based on fines or litigation records during the past two years. Minor Change From five years to two years to avoid overlap of data collection and analysis between Indexes.  
  *evidence to refer to fines or reports/controversies  
  **excluding all IP anti-competitive practices |
| **B.III.3 Lobbying, ethical marketing, anti-bribery/ anti-corruption**   | Part a - The company has taken disciplinary action against third parties or employees who violate its code of conduct for ethical marketing or lobbying and anti-corruption. Part b (qualitative-no scoring) - The company has established stringent enforcement mechanisms for disciplinary action against third parties or employees that violate its codes of conduct for ethical marketing or lobbying and anti-corruption. |

Note: unless otherwise specified, indicator has remained the same as in the 2012 Index
<table>
<thead>
<tr>
<th>2014 Indicator</th>
<th>Change/ rationale</th>
</tr>
</thead>
</table>
| B.III.4 Lobbying | **New 2014**  
Moved from Patents & Licencing section as indicator focuses on lobbying. Wording changed to be more specific of expectations of company performance surrounding trade negotiations. |
| B.IV Innovation - 10% | **Minor Change**  
Removed efficient to focus on ethical behaviour and include innovative direct advocacy activities. |
| B.IV.1 Innovation in public policy & market influence | The company has adopted an innovative (unique in the sector), sustainable approach to improving ethical business performance and interactions in Index Countries in areas relevant to increasing access to medicine such as marketing, advocacy, lobbying, anti-corruption, and pro-competition. |
### C  Research & Development

#### 2014 Indicator | Change/ rationale
--- | ---
**C.1 Commitments - 25%** |  
C.1.1 Innovative and adaptive R&D for Index Diseases
The company commits to carry out research focusing on the development of both innovative and new remedies for the Index Diseases and adaptive new formulations of its existing products for the Index Diseases with the goal of improving access to medicine in the Index Countries.  

C.1.2 Collaborative R&D
The company commits to ensuring equitable access to products successfully developed through R&D partnerships.  

C.1.3 Clinical trial conduct
The company commits to compliance with quality assurance and control, plus ethical standards when conducting clinical trials in Index Countries, consistent with codes such as Good Clinical Practice and the Declaration of Helsinki (regardless of whether the trials are conducted in-house or through a third-party, e.g. CRO).  

**C.2 Transparency - 25%** |  
C.2.1 Resources towards R&D
The company discloses the resources dedicated to its research and development activities conducted in-house and/or in collaboration for Index Diseases suitable for Index Countries.  

C.2.2 Collaborative R&D
The company discloses the licencing details pertaining to its research collaborations related to the Index Diseases (with regard to Intellectual Property rights, access provisions etc.).  

C.2.3 R&D for Index Diseases suitable to Index Countries’ needs
The company discloses its research pipeline related to both in-house research and collaborations targeting Index Diseases (where disclosure is not legally required).  

C.2.4 Clinical trial data
The company discloses information and results of all of its clinical trials conducted in Index Countries, regardless of the outcome and whether the trial was conducted in-house or through a third-party (e.g. CRO).  

**Minor Change**  
Expand to availability of clinical trial information in registries of all clinical trials performed in Index Countries, plus publicly available clinical trial data.  

Note: unless otherwise specified, indicator has remained the same as in the 2012 Index
<table>
<thead>
<tr>
<th>2014 Indicator</th>
<th>Change/ rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>C.III Performance - 40%</strong></td>
<td></td>
</tr>
<tr>
<td><strong>C.III.1 Resources towards R&amp;D</strong></td>
<td>Portion of financial R&amp;D investments dedicated to Index Diseases out of the company's total R&amp;D expenditures.</td>
</tr>
<tr>
<td><strong>C.III.2 R&amp;D for Index Diseases suitable to Index Countries' needs</strong></td>
<td>Share of research pipeline reflecting 'new molecules' for Index Diseases including in-house and collaborative research.</td>
</tr>
<tr>
<td><strong>C.III.3 R&amp;D for Index Diseases suitable to Index Countries' needs</strong></td>
<td>Share of research pipeline and products registered reflecting 'adapted products or new technologies' specific to an Index Disease and an unmet need in an Index Country, including in-house and collaborative research. Minor Change Clarification of wording.</td>
</tr>
<tr>
<td><strong>C.III.4 Collaborative R&amp;D</strong></td>
<td>R&amp;D partnerships in which the company has been involved, with the aim of developing products or formulations for Index Diseases specifically targeting access issues in Index Countries (adjusted for the number of molecules in the company’s research pipeline). Minor Change Clarification of wording.</td>
</tr>
<tr>
<td><strong>C.III.5 R&amp;D for Index Diseases suitable to Index Countries' needs</strong></td>
<td>Number of candidates relating to Index Diseases moving through research and development life cycle from early research phases to more advanced phases.</td>
</tr>
<tr>
<td><strong>C.III.6 Collaborative R&amp;D</strong></td>
<td>The company provides evidence that the terms and conditions of its research collaborations are conducive to improving access to Index Disease products in the Index Countries for the individuals with significant financial barriers to access.</td>
</tr>
<tr>
<td><strong>C.III.7 Clinical trial conduct</strong></td>
<td>Has the company been the subject of any breach of international codes or lawsuits related to its clinical trial practices in the Index Countries during the last five years?</td>
</tr>
<tr>
<td><strong>C.III.8 IP sharing</strong></td>
<td>The company provides evidence of sharing its intellectual capital (e.g. molecules library, patented compounds, processes or technologies) with research institutions and neglected disease drug discovery initiatives (e.g. WIPO Re: Search, CDD, OSDD) that develop products for Index Diseases on terms most conducive to access to medicine for the Index Countries. Minor Change Clarification of wording.</td>
</tr>
<tr>
<td>2014 Indicator</td>
<td>Change/ rationale</td>
</tr>
<tr>
<td>---------------</td>
<td>------------------</td>
</tr>
<tr>
<td><strong>C.III.9</strong> Clinical trial conduct</td>
<td>Minor Change Expand to quality and ethical compliance of both in-house and CRO conducted clinical trials.</td>
</tr>
<tr>
<td>The company provides evidence of ensuring compliance with Good Clinical Practice and the Declaration of Helsinki when conducting trials in Index Countries, regardless of whether the trial was conducted in-house or through a third-party (e.g. CRO).</td>
<td></td>
</tr>
</tbody>
</table>

| C.IV | Innovation - 10% |
| C.IV.1 Innovation in R&D | The company has adopted innovative (unique in the sector), sustainable or open business models to further the global R&D agenda for the development of products for Index Diseases. |

Note: unless otherwise specified, indicator has remained the same as in the 2012 Index
## D Pricing, Manufacturing & Distribution

<table>
<thead>
<tr>
<th>2014 Indicator</th>
<th>Change/ rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>D.1 Commitments - 25%</strong></td>
<td></td>
</tr>
<tr>
<td><strong>D.I.1 Equitable pricing strategies</strong></td>
<td>Major Change Expanded to include all equitable pricing models.</td>
</tr>
<tr>
<td>The company commits to implement equitable inter-country pricing models for the products related to the Index Diseases in the Index Countries to ensure affordability.</td>
<td></td>
</tr>
<tr>
<td><strong>D.I.2 Equitable pricing strategies</strong></td>
<td>Major Change Expanded to include all equitable pricing models.</td>
</tr>
<tr>
<td>The company commits to implement equitable intra-country pricing models for the products related to the Index Diseases in the Index Countries to ensure affordability.</td>
<td></td>
</tr>
<tr>
<td><strong>D.I.3 Accountability for sales agents’ pricing practices</strong></td>
<td></td>
</tr>
<tr>
<td>The company adopts clear policies to control the pricing practices of its local sales agents with the aim of improving affordability and accessibility of the products.</td>
<td></td>
</tr>
<tr>
<td><strong>D.I.4 Drug recalls</strong></td>
<td></td>
</tr>
<tr>
<td>The company has in place the policies, procedures and resources needed to carry out effective drug recalls (product and packaging) in the Index Countries where it operates.</td>
<td></td>
</tr>
<tr>
<td><strong>D.I.5 Brochure &amp; packaging adaptation</strong></td>
<td></td>
</tr>
<tr>
<td>The company commits to needs-based (facilitation of rational use) brochure and packaging adaptation for its products destined for Index Countries (at least equal to local regulatory requirements).</td>
<td></td>
</tr>
<tr>
<td><strong>D.I.6 Filing for marketing approval/registration</strong></td>
<td></td>
</tr>
<tr>
<td>The company commits to file for marketing approval or product registration of its products for the Index Diseases in the Index Countries in need.</td>
<td></td>
</tr>
<tr>
<td><strong>D.II Transparency - 25%</strong></td>
<td></td>
</tr>
<tr>
<td><strong>D.II.1 Equitable pricing schemes</strong></td>
<td>Major Change To include disclosure of volume of sales as a measure of affordable pricing strategies (Piloted).</td>
</tr>
<tr>
<td>The company discloses the volume of its sales to the lower tiers covered under equitable pricing programs to ensure affordability.</td>
<td></td>
</tr>
<tr>
<td><strong>D.II.2 Equitable pricing schemes</strong></td>
<td>Major Change To measure disclosure of price points offered to poorest tiers &amp; the companies’ rationale behind setting these prices (Piloted).</td>
</tr>
<tr>
<td>For equitably priced products relating to the Index Diseases in the Index Countries, the company discloses target prices for the lower tiers and how it determines these prices.</td>
<td></td>
</tr>
<tr>
<td>2014 Indicator</td>
<td>Change/ rationale</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>D.III.3</strong> Filing for marketing approval/registration</td>
<td>Minor Change</td>
</tr>
<tr>
<td>The company discloses its decision-making process regarding registration</td>
<td>Clarification of wording.</td>
</tr>
<tr>
<td>(marketing approval) and also the status of marketing approvals for each</td>
<td></td>
</tr>
<tr>
<td>product related to Index Diseases in the Index Countries.</td>
<td></td>
</tr>
<tr>
<td><strong>D.II.4</strong> Drug recalls</td>
<td>Minor Change</td>
</tr>
<tr>
<td>The company publicly discloses information about the drug recalls and breaches</td>
<td>Clarification of wording.</td>
</tr>
<tr>
<td>it has been involved in related to drug quality issues in the Index Countries.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>D.III</strong> Performance - 40%</td>
<td></td>
</tr>
<tr>
<td><strong>D.III.1</strong> Equitable pricing strategies</td>
<td>Minor Change</td>
</tr>
<tr>
<td>Do the company’s equitable pricing programmes for products relating to Index</td>
<td>Clarification of wording.</td>
</tr>
<tr>
<td>Diseases cover all or a significant percentage of Index Countries?</td>
<td></td>
</tr>
<tr>
<td><strong>D.III.2</strong> Equitable pricing strategies</td>
<td>Major Change</td>
</tr>
<tr>
<td>Does the company take into consideration needs-based affordability when</td>
<td>To meaningfully compare pricing strategies</td>
</tr>
<tr>
<td>making pricing decisions for relevant products targeted at the poorest</td>
<td>across a diverse range of products, countries and companies (Piloted).</td>
</tr>
<tr>
<td>population segments in relevant countries?</td>
<td></td>
</tr>
<tr>
<td><strong>D.III.3</strong> Filing for marketing approval/registration</td>
<td>Minor Change</td>
</tr>
<tr>
<td>Has the company attempted to register (obtain marketing approval for) its</td>
<td></td>
</tr>
<tr>
<td>products for Index Diseases in the Index Countries in need?</td>
<td></td>
</tr>
<tr>
<td><strong>D.III.4</strong> Drug recalls</td>
<td>Minor Change</td>
</tr>
<tr>
<td>Have drug recalls occurred due to product or packaging quality issues in the</td>
<td>Include company response to drug recalls</td>
</tr>
<tr>
<td>Index Countries for products produced by the company, its licencees or other</td>
<td>and change from five years to two years to avoid overlap of data collection and</td>
</tr>
<tr>
<td>manufacturing partners during the past two years? If so, how has the company</td>
<td>analysis between Indices.</td>
</tr>
<tr>
<td>dealt with them?</td>
<td></td>
</tr>
<tr>
<td><strong>D.III.5</strong> Filing for marketing approval/registration</td>
<td></td>
</tr>
<tr>
<td>The company files for WHO Prequalification list, tentative approval of US</td>
<td></td>
</tr>
<tr>
<td>Food and Drug Administration, European Medicines Agency or other stringent</td>
<td></td>
</tr>
<tr>
<td>regulatory authority approval for its eligible products for the Index Diseases.</td>
<td></td>
</tr>
<tr>
<td><strong>D.III.6</strong> Equitable pricing schemes</td>
<td></td>
</tr>
<tr>
<td>Do products for Index Diseases destined for Index Countries for which tiered</td>
<td></td>
</tr>
<tr>
<td>pricing is used have special packaging or other distinct markers to prevent</td>
<td></td>
</tr>
<tr>
<td>product diversion?</td>
<td></td>
</tr>
</tbody>
</table>

Note: unless otherwise specified, indicator has remained the same as in the 2012 Index
**2014 Indicator**

**Change/ rationale**

---

**D.IV Innovation - 10%**

**D.IV.1 Innovation in equitable pricing**

The company has introduced innovative approaches (unique in the sector) to equitable pricing which help with sustainable delivery of the products for Index Diseases to individuals in the Index Countries who face the highest financial barriers to access.

**D.IV.2 Innovation in manufacturing & distribution**

The company has introduced innovative approaches (unique in the sector) to manufacturing and distribution of products for the Index Diseases which may help with sustainable delivery of such products for the Index Diseases in the Index Countries.
## Patents & Licencing

<table>
<thead>
<tr>
<th>E.I</th>
<th>Commitments - 25%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>E.I.1</strong> Patent filings</td>
<td>The company commits to not file for or enforce patents related to its products for the Index Diseases in LDCs, LICs and LMICs.</td>
</tr>
<tr>
<td><strong>Change/ rationale</strong></td>
<td><strong>Major Change</strong></td>
</tr>
<tr>
<td></td>
<td>To expand the scope to LICs and LMICs in addition to LDCs.</td>
</tr>
<tr>
<td><strong>E.I.2</strong> IP strategies</td>
<td>The company commits as part of a wider access-oriented strategy to issue non-exclusive voluntary licencing (NEVL) or binding non-assert declarations (NAD) for manufacturing and supply of the patented product.</td>
</tr>
<tr>
<td><strong>Change/ rationale</strong></td>
<td><strong>Minor Change</strong></td>
</tr>
<tr>
<td></td>
<td>To refine the expectation of relevant licences utilised for promoting competition and increased access.</td>
</tr>
</tbody>
</table>

## Transparency - 25%

<table>
<thead>
<tr>
<th>E.II</th>
<th>Transparency - 25%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>E.II.1</strong> TRIPS flexibilities</td>
<td>The company discloses its explicit support of usage of TRIPS flexibilities based on the Doha Declaration on TRIPS and public health.</td>
</tr>
<tr>
<td><strong>E.II.2</strong> Patent filings</td>
<td>The company discloses the patent status of its products for the Index Diseases in the Index Countries.</td>
</tr>
<tr>
<td><strong>E.II.3</strong> IP strategies</td>
<td>The company discloses detailed information about the voluntary licencing activities it is engaged in and its binding non-assert clauses for products related to the Index Diseases for the Index Countries (such as licence duration, licence territory, technology transfer, etc.).</td>
</tr>
</tbody>
</table>

## Performance - 40%

<table>
<thead>
<tr>
<th>E.III</th>
<th>Performance - 40%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>E.III.1</strong> IP strategies</td>
<td>Does the company actively engage in issuing multiple non-exclusive voluntary licences and/or use legally binding non-assert declarations/clauses for the Index Countries for its products related to the Index Diseases?</td>
</tr>
<tr>
<td><strong>Change/ rationale</strong></td>
<td><strong>Minor Change</strong></td>
</tr>
<tr>
<td></td>
<td>Clarification of wording.</td>
</tr>
<tr>
<td><strong>E.III.2</strong> Technology transfer</td>
<td>Does the company have technology transfer agreements that accelerate and facilitate generic product development?</td>
</tr>
<tr>
<td><strong>Change/ rationale</strong></td>
<td><strong>Minor Change</strong></td>
</tr>
<tr>
<td></td>
<td>Emphasis on access to medicine and public health-oriented components of agreements versus milestones.</td>
</tr>
</tbody>
</table>

Note: unless otherwise specified, indicator has remained the same as in the 2012 Index
<table>
<thead>
<tr>
<th>2014 Indicator</th>
<th>Change/ rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>E.III.3</strong> IP strategies</td>
<td>The company supports patent pools such as The Medicines Patent Pool for development of new/adaptive remedies for the Index Diseases in the Index Countries.</td>
</tr>
<tr>
<td><strong>E.III.4</strong> IP strategies</td>
<td>Are the contents of the non-exclusive voluntary licencing and/or legally binding non-assert declarations/clauses access-oriented for its products related to the Index Diseases in Index Countries?</td>
</tr>
<tr>
<td><strong>New 2014</strong></td>
<td>To capture the quality of licences and key access provisions.</td>
</tr>
<tr>
<td><strong>E.III.5</strong> IP strategies</td>
<td>Is there evidence that the company employs an IP strategy that is conducive to access to affordable products for Index Diseases in the Index Countries (e.g. actively engage in pro-competitive approaches by avoiding anti-competitive practices such as evergreening, thicketing, protection of research tools etc.)?</td>
</tr>
<tr>
<td><strong>Minor Change</strong></td>
<td>Clarification of wording.</td>
</tr>
</tbody>
</table>

**E.IV Innovation - 10%**

**E.IV.1 Innovation in patents and licencing**

The company has engaged in innovative (unique in the sector), sustainable programmes aimed at decreasing the impact of the exclusivity conferred by patent protection that could result in increased affordability and accessibility of medicine to individuals with financial barriers to access (e.g. adopted innovative socially responsible licencing practices aiming at increased effectiveness of its licencing programmes).
## F Capability Advancement in Product Development & Distribution

<table>
<thead>
<tr>
<th>2014 Indicator</th>
<th>Change/ rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>F.1 Commitments - 25%</strong></td>
<td></td>
</tr>
<tr>
<td><strong>F.I.1 Capacity building in QMS and manufacturing standards</strong></td>
<td>Minor Change, Clarification of wording.</td>
</tr>
<tr>
<td>The company commits to assist Index Country manufacturers in building quality management systems aimed at achieving international quality standards (e.g. FDA, EMA, WHO Good Manufacturing Practices or recognised national certifications) and ensure that local staff employed at in-house facilities operating in Index Countries follow the same standards.</td>
<td></td>
</tr>
<tr>
<td><strong>F.I.2 Capacity building in pharmacovigilance</strong></td>
<td></td>
</tr>
<tr>
<td>The company commits to support the development and/or implementation of national pharmacovigilance programmes in the Index Countries.</td>
<td></td>
</tr>
<tr>
<td><strong>F.II Transparency - 25%</strong></td>
<td></td>
</tr>
<tr>
<td><strong>F.II.1 Capacity building in pharmacovigilance</strong></td>
<td>Major Change, Extend pharmacovigilance disclosure to include measure of what companies disclose to governments.</td>
</tr>
<tr>
<td>The company discloses details of its capability advancement activities related to the development and/or implementation of national pharmacovigilance programmes and the company discloses post-marketing surveillance data to Index Country governments.</td>
<td></td>
</tr>
<tr>
<td><strong>F.II.2 Capacity building in QMS and manufacturing standards</strong></td>
<td>New 2014, To capture transparency in companies’ local manufacturing quality standards to ensure they meet required standards.</td>
</tr>
<tr>
<td>The company discloses details of its local in-house facilities’ quality standards and details of contracts with local manufacturers (including licencees and contract manufacturers) that evidence obligations to maintain good quality standards similar to those it applies internally in developed countries or at least consistent with international standards such as the FDA, EMA and/or WHO Good Manufacturing Practices.</td>
<td></td>
</tr>
<tr>
<td><strong>F.II.3 Capacity building in R&amp;D</strong></td>
<td>New 2014, To capture transparency in companies’ local research partnerships to measure how they advance local capacity.</td>
</tr>
<tr>
<td>The company discloses details of its partnerships/collaborations with Index Country public sector research institutes or universities evidencing how they aim to create local research capacity and product development for Index Diseases.</td>
<td></td>
</tr>
<tr>
<td><strong>F.II.4 Capacity building in supply chain management</strong></td>
<td>New 2014, To capture transparency in companies’ collaborations across the local supply chain and how they improve local supply chain management.</td>
</tr>
<tr>
<td>The company discloses details of how it is transparent with other stakeholders across the supply chain to enhance local capabilities by preventing product diversion, stock-outs, counterfeiting, information gaps and improving demand forecasting and drug regulation.</td>
<td></td>
</tr>
</tbody>
</table>

Note: unless otherwise specified, indicator has remained the same as in the 2012 Index
<table>
<thead>
<tr>
<th>2014 Indicator</th>
<th>Change/ rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>F.III</strong></td>
<td><strong>Performance - 40%</strong></td>
</tr>
</tbody>
</table>
| **F.III.1** Capacity building in QMS and manufacturing standards | Minor Change  
Clarification of wording to specify technology transfer.  
Is there evidence that the company assists local Index Country manufacturers or in-house manufacturing facilities to achieve international good manufacturing standards* in the Index Countries through training or technology transfer?  
* Such as FDA, EMA or the WHO Good Manufacturing Practices or equally recognised national certifications. |
| **F.III.2** Capacity building in R&D |  
Is there evidence that the company participates in local partnerships with public sector research institutes or universities in the Index Countries with the aim of increasing local capacity for health research (including clinical trials capacity) and product development? |
| **F.III.3** Capacity building in supply chain management |  
The company is engaged in programmes/partnerships with Index Country governments (e.g. MoH/procurement, logistics and distribution agencies) and other distributors to develop locally appropriate supply chain capabilities with the aim of improving affordability, accessibility and quality of the delivered Index Disease products. |
| **F.III.4** Capacity building in pharmacovigilance |  
The company is actively engaged in developing and implementing national pharmacovigilance-related programmes in the Index Countries. |
| **F.III.5** Initiatives to build other capacities |  
The company carries out other initiatives (where there is no conflict of interest) with potential for improving capacity of Index Country organisations to address access to medicine in those countries. |
| **F.IV** | **Innovation - 10%** |
| **F.IV.1** Innovation in capability advancement | Major Change  
Expand to include all four areas of Capability Advancement in this indicator.  
The company has introduced innovative (unique in the sector) approaches to local capacity advancement, working with Index Country organisations to improve the quality and accessibility of products for Index Diseases. |
## Product Donations and Philanthropic Activities

### G.1 Commitments - 25%

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Description</th>
<th>Change/ rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>G.I.1 Drug donations</td>
<td>The company commits to comply with the WHO Guidelines for Medicine Donations – Revised 2010 in the Index Countries for all its drug donation activities.</td>
<td>Minor Change Updated to Revised WHO Guidelines.</td>
</tr>
<tr>
<td>G.I.2 Drug donations</td>
<td>The company commits to ensuring that donated products are administered to patients in the Index Countries.</td>
<td></td>
</tr>
<tr>
<td>G.I.3 Sustainable philanthropy</td>
<td>The company commits to and explains its rationale for investing in health infrastructure-related philanthropic projects (outside of the standard value chain) in the Index Countries and their relevance to long-term sustainable access to medicine in Index Countries.</td>
<td></td>
</tr>
</tbody>
</table>

### G.II Transparency - 25%

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Description</th>
<th>Change/ rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>G.II.1 Drug donations</td>
<td>The company discloses the process and criteria for deciding the drug types and destinations for its single-drug donation programmes in the Index Countries.</td>
<td></td>
</tr>
<tr>
<td>G.II.2 Drug donations</td>
<td>The company discloses detailed information about the type, volume and destination of products that are part of its multi-drug donation programmes donated in the Index Countries.</td>
<td></td>
</tr>
<tr>
<td>G.II.3 Sustainable philanthropy</td>
<td>The company discloses the amount of resources dedicated to and achievements resulting from its philanthropic activities in the Index Countries.</td>
<td></td>
</tr>
</tbody>
</table>

Note: unless otherwise specified, indicator has remained the same as in the 2012 Index
### 2014 Indicator Change/ rationale

<table>
<thead>
<tr>
<th>2014 Indicator</th>
<th>Change/ rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>G.III Performance - 40%</strong></td>
<td>Minor Change Clarification of wording.</td>
</tr>
<tr>
<td><strong>G.III.1 Drug donations</strong></td>
<td>The company monitors outcomes and impact of single-drug donation programmes during the reporting period.</td>
</tr>
<tr>
<td><strong>G.III.2 Drug donations</strong></td>
<td>The value of donated products which were donated based on targeted, needs-based strategic donations programmes to the Index Countries during the period of analysis (single-drug donations adjusted for the company size).</td>
</tr>
<tr>
<td><strong>G.III.3 Drug donations</strong></td>
<td>The scale and scope of donated products to the Index Countries during the period of analysis.</td>
</tr>
<tr>
<td><strong>G.III.4 Sustainable philanthropy</strong></td>
<td>There is evidence that the company’s philanthropic activities (excluding drug donation programmes) are aligned with and support implementation of national health system development plans and stated health priorities in the Index Countries.</td>
</tr>
<tr>
<td><strong>G.IV Innovation - 10%</strong></td>
<td></td>
</tr>
<tr>
<td><strong>G.IV.1 Innovation in product donations</strong></td>
<td>The company has introduced innovative (unique in the sector), sustainable and impactful approaches to managing drug donations, which may result in increased effectiveness and efficacy.</td>
</tr>
<tr>
<td><strong>G.IV.2 Innovation in sustainable philanthropy</strong></td>
<td>The company has introduced innovative (unique in the sector) approaches to philanthropic programmes to make it more sustainable and linked to better health outcomes in the Index Countries, which may result in sustainable health improvements.</td>
</tr>
</tbody>
</table>

Note: unless otherwise specified, indicator has remained the same as in the 2012 Index.
Appendix 1: Review & Consultations
Between January and October 2013, the Index team engaged with stakeholders in a variety of settings to understand multiple perspectives and stay up-to-date on developments in the dynamic access to medicine landscape. Information and insights gathered during these dialogues were incorporated into the Foundation’s internal methodology review process and consultations with the Technical Subcommittees (TSCs) and Expert Review Committee (ERC).

Online survey & company results calls
From February 12th to March 4th, 2013, the Foundation invited Index readers, contributors and representatives from relevant stakeholder groups to share their feedback on various aspects of the development of the 2012 Index, from the methodology to the presentation of the 2012 Index results. A total of 134 people representing seven stakeholder groups throughout the world responded. Pharmaceutical industry representatives were most prevalent within the survey respondent group.

Between January and April 2013, the Foundation offered representatives of all 20 companies measured in the 2012 Index the opportunity to give their feedback on Index methodology, processes and results in individual conference calls with the 2012 Index team. Eleven of the 20 companies measured by the Index participated in these calls.

Feedback from both the survey and the company calls indicated that stakeholders’ perceptions of the Index are evolving. Not only is the Index valued for its ability to compare companies’ access to medicine initiatives, but increasingly stakeholders - including pharmaceutical companies - are looking to the Index for guidance on expectations and best practices. At the same time, some stakeholders remain watchful, and sometimes critical, of what and how the Index measures. This criticism is important in helping the Index team to understand stakeholders' expectations as it continually looks for ways to make the Index as relevant and informative as possible.

Strategic Access to Medicine Workshop
In May 2013, representatives of companies measured by the Index gathered near Amsterdam for a Strategic Access to Medicine Workshop to discuss how more inclusive business models can be developed to incorporate access strategies into core business, and how best practices can be shared. Participants concluded that creating internal support for access to medicine strategies, taking advantage of opportunities for industry-wide collaboration, and recognising external stakeholder expectations are important ways to move forward in this area.

Stakeholder Dialogue: Ensuring Quality Affordable Medicines in Developing Countries
In June 2013, members of the Index team travelled to Accra, Ghana to host a multi-stakeholder dialogue in Ghana of key experts from developing countries to discuss important issues identified in the 2012 Access to Medicine Index. Over the course of 1.5 days, participants debated how to define and measure affordability as well as the best ways to monitor safety and quality of medicines. It was concluded that strong definitions and standards for affordable
pricing as well as better comparability between tiered pricing programmes are needed, and that regional harmonisation of regulatory approaches is the way forward for pharmacovigilance. It was also clear that both research-based and generics companies have an important role to play in ensuring safe, affordable medicines in countries covered by the Index.

**Investor dialogue**

In addition to multiple investor consultations throughout the year, Foundation members attended a series of meetings in Paris with representatives of both mainstream and socially responsible investment (SRI) firms in September 2013. The discussions focused on how the Index can be used as a tool for investors to better understand potential risks, opportunities and best practices for access to medicine in low- and middle-income countries. Investors stated that many Index indicators are already relevant to their work. They suggested that including more emerging economies, measuring companies’ long-term performance, and the risks associated with their access to medicine activities, could further increase the utility of the Index for them.

### Committee consultation process

**Technical Subcommittees**

Between February and September 2013, the Foundation’s research team convened groups of experts to serve as Technical Subcommittees (TSCs) for Technical Areas in the methodology framework. These TSCs gave specific input and advice in response to the team’s proposals for the Technical Areas of Public Policy & Market Influence; Research & Development; Pricing, Manufacturing & Distribution and Patents & Licensing in the 2014 Index methodology. For the remaining Technical Areas of General Access to Medicine Management, Capability Advancement and Donations & Philanthropy, experts were consulted individually but did not convene as TSCs.

TSCs were convened for at least one meeting and, if necessary, reconvened for follow-up discussions. Suggestions from TSCs were integrated into proposals for the Expert Review Committee. Where necessary, the Expert Review Committee’s feedback to the TSC’s initial suggestions was subsequently discussed with TSCs to go over any additional considerations. The final TSC comments were incorporated into the final 2014 Index methodology proposal for approval by the ERC in September 2013.

**Expert Review Committee**

The Foundation’s research team met with the Expert Review Committee (ERC) in April, June and September 2013. The role of the ERC is to provide the Foundation with strategic guidance with regard to the Index’s scope and indicators in each of the seven Technical Areas.

In June 2013, the ERC was presented with the draft methodology framework proposal for the 2014 Access to Medicine Index. Based on the ERC’s feedback, the research team conducted pilot tests with companies in order to determine the feasibility of potential new indicators within the General Access to Medicine Management, Pricing, Manufacturing & Distribution Technical Areas. Following the integration of initial comments, the reconvened TSCs where applicable, and the results of the pilots, the ERC gave its support to the final methodology proposal for the 2014 Index at a meeting in September 2013.
Contributors to this report

Expert Review Committee
• Hans Hogerzeil, University of Groningen, Switzerland
• Marja Esveld, Ministry of Health, The Netherlands
• Richard Laing, World Health Organization (WHO), Switzerland
• Dennis Ross-Degnan, Harvard University, USA
• Regina Kamoga, Community Health and Information Network (CHAIN), Uganda
• Natacha Dimitrijevic, Hermes Equity Ownership Services, UK
• Peter Shelby, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Switzerland
• Dilip Shah, Indian Pharmaceutical Alliance, India

Technical Subcommittees
B Public Policy & Market Influence
• Michele Forzley, Georgetown University Law Center, USA
• Jillian Kohler, University of Toronto, Canada

C Research & Development
• Jennifer Dent, Bio Ventures for Global Health, USA
• Javier Guzman, Policy Cures, UK

D Pricing Manufacturing & Distribution
• Jaime Espin, Andalusian School of Public Health, Spain
• Niranjan Konduri, Management Sciences for Health, USA
• Prashant Yadav, University of Michigan, USA

E Patents & Licencing
• Peter Beyer, World Health Organization (WHO), Switzerland
• Esteban Burrone, Medicines Patent Pool, Switzerland
• Warren Kaplan, Boston University, USA

Additional contributors
• Afshin Mehrpouya, Hautes études commerciales (HEC) Paris, France
• Rachelle Harris, Department for International Development (DFID), UK
• 'Strategic Access to Medicine Workshop' participants, May 2013, Amstelveen, The Netherlands
• 'Stakeholder Dialogue: Ensuring quality affordable medicine in developing countries' participants, June 2013, Accra, Ghana
• 'Investor Dialogue' participants, September 2013, Paris, France
Appendix 2:
ICD-10 Coverage
### ICD-10 Coverage

<table>
<thead>
<tr>
<th>Table 5</th>
<th>ICD-10 Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Global DALYs</strong></td>
<td><strong>Index Disease</strong></td>
</tr>
<tr>
<td><strong>Communicable Diseases</strong></td>
<td></td>
</tr>
</tbody>
</table>
| 1 | 94,511 | Lower respiratory infections | J10 – Influenza due to other identified influenza virus  
J11 – Influenza, virus not identified  
J12 – Viral pneumonia, not elsewhere classified  
J13 – Pneumonia due to Streptococcus brupont  
J14 – Pneumonia due to Haemophilus brupont  
J15 – Bacterial pneumonia, not elsewhere classified  
J16 – Pneumonia due to other infectious organisms, not elsewhere classified  
J17 – Pneumonia in diseases classified elsewhere  
J18 – Pneumonia, organism unspecified  
J20 – Acute bronchitis  
J21 – Acute bronchiolitis  
J22 – Unspecified acute lower respiratory infection |
| 2 | 72,777 | Diarrhoeal diseases | A00 – Cholera  
A01 – Typhoid and paratyphoid fevers  
A03 – Shigellosis  
A04 – Other bacterial intestinal infections  
A06 – Amoebiasis  
A07 – Other protozoal intestinal diseases  
A08 – Viral and other specified intestinal infections  
A09 – Other gastroenteritis and colitis of infectious and unspecified origin |
| 3 | 58,513 | HIV/AIDS | B20 – Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseases  
B21 – Human immunodeficiency virus [HIV] disease resulting in malignant neoplasms  
B22 – Human immunodeficiency virus [HIV] disease resulting in other specified diseases  
B23 – Human immunodeficiency virus [HIV] disease resulting in other conditions  
B24 – Unspecified human immunodeficiency virus [HIV] disease |
| 4 | 34,217 | Tuberculosis | A15 – Respiratory tuberculosis, bacteriologically and histologically confirmed  
A16 – Respiratory tuberculosis, not confirmed bacteriologically or histologically  
A17 – Tuberculosis of nervous system  
A18 – Tuberculosis of other organs  
A19 – Miliary tuberculosis |
| 5 | 33,976 | Malaria | B50 – Plasmodium falciparum malaria  
B51 – Plasmodium vivax malaria  
B52 – Plasmodium malariae malaria  
B53 – Other parasitologically confirmed malaria  
B54 – Unspecified malaria |
| 6 | 14,853 | Measles | B05 – Measles |
| 7 | 11,426 | Meningitis | A39 – Meningococcal infection  
G00 – Bacterial meningitis, not elsewhere classified  
G03 – Meningitis due to other and unspecified causes |
| 8 | 9,882 | Pertussis | A37 – Whooping cough |
| 9 | 5,283 | Tetanus | A33 – Tetanus neonatorum  
A35 – Other tetanus |
| 10 | 3,748 | Chlamydia | A55 – Chlamydial lymphogranuloma (venereum)  
A56 – Other sexually transmitted chlamydial diseases |
<table>
<thead>
<tr>
<th>Global DALYs</th>
<th>Index Disease</th>
<th>Name</th>
<th>ICD-10 Classifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>65,472</td>
<td>Unipolar depressive disorders</td>
<td>1</td>
<td>F32 – Depressive episode</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>F33 – Recurrent depressive disorder</td>
</tr>
<tr>
<td>62,587</td>
<td>Ischaemic heart disease</td>
<td>3</td>
<td>I20 – Angina pectoris</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I21 – Acute myocardial infarction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I22 – Subsequent myocardial infarction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I23 – Certain current complications following acute myocardial infarction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I24 – Other acute ischaemic heart diseases</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I25 – Chronic ischaemic heart disease</td>
</tr>
<tr>
<td>46,591</td>
<td>Cerebrovascular disease</td>
<td>4</td>
<td>I60 – Subarachnoid haemorrhage</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I61 – Intracerebral haemorrhage</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I62 – Other nontraumatic intracranial haemorrhage</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I63 – Cerebral infarction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I64 – Stroke, not specified as haemorrhage or infarction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I65 – Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I66 – Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I67 – Other cerebrovascular diseases</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I68 – Cerebrovascular disorders in diseases classified elsewhere</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I69 – Sequelae of cerebrovascular disease</td>
</tr>
<tr>
<td>30,196</td>
<td>Chronic obstructive pulmonary disorder [COPD]</td>
<td>5</td>
<td>J40 – Bronchitis, not specified as acute or chronic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>J41 – Simple and mucopurulent chronic bronchitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>J42 – Unspecified chronic bronchitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>J43 – Emphysema</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>J44 – Other chronic obstructive pulmonary disease</td>
</tr>
<tr>
<td>19,705</td>
<td>Diabetes mellitus</td>
<td>6</td>
<td>E10 – Insulin-dependent diabetes mellitus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E11 – Non-insulin-dependent diabetes mellitus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E12 – Malnutrition-related diabetes mellitus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E13 – Other specified diabetes mellitus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E14 – Unspecified diabetes mellitus</td>
</tr>
<tr>
<td>16,769</td>
<td>Schizophrenia</td>
<td>7</td>
<td>F20 – Schizophrenia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F21 – Schizotypal disorder</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F22 – Persistent delusional disorders</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F23 – Acute and transient psychotic disorders</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F24 – Induced delusional disorder</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F25 – Schizoaffective disorders</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F28 – Other nonorganic psychotic disorders</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F29 – Unspecified nonorganic psychosis</td>
</tr>
<tr>
<td>16,317</td>
<td>Asthma</td>
<td>8</td>
<td>J45 – Asthma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>J46 – Status asthmaticus</td>
</tr>
<tr>
<td>15,586</td>
<td>Osteoarthritis</td>
<td>9</td>
<td>M15 – Polyarthritis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M16 – Coxarthrosis [arthrosis of hip]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M17 – Gonarthrosis [arthrosis of knee]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M18 – Arthrosis of first carpometacarpal joint</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M19 – Other arthrosis</td>
</tr>
<tr>
<td>14,425</td>
<td>Bipolar affective disorder</td>
<td>10</td>
<td>F30 – Manic episode</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F31 – Bipolar affective disorder</td>
</tr>
<tr>
<td>13,640</td>
<td>Cirrhosis of the liver</td>
<td>11</td>
<td>K70 – Alcoholic liver disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>K74 – Fibrosis and cirrhosis of liver</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B18 – Chronic viral hepatitis</td>
</tr>
<tr>
<td>Global DALYs</td>
<td>Index Disease</td>
<td>Name/ICD-10 Classifications</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>--------------</td>
<td>-----------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 9,057       | Nephritis and nephrosis | N00 – Acute nephritic syndrome  
N01 – Rapidly progressive nephritic syndrome  
N02 – Recurrent and persistent haematuria  
N03 – Chronic nephritic syndrome  
N04 – Nephrotic syndrome  
N05 – Unspecified nephritic syndrome  
N06 – Isolated proteinuria with specified morphological lesion  
N07 – Hereditary nephropathy, not elsewhere classified  
N08 – Glomerular disorders in diseases classified elsewhere  
N10 – Acute brupt-interstitial nephritis  
N11 – Chronic brupt-interstitial nephritis  
N12 – Tubulo-interstitial nephritis, not specified as acute or chronic  
N13 – Obstructive and reflex uropathy  
N14 – Drug- and heavy-metal-induced brupt-interstitial and tubular conditions  
N15 – Other renal brupt-interstitial diseases  
N16 – Renal brupt-interstitial disorders in diseases classified elsewhere  
N17 – Acute renal failure  
N18 – Chronic kidney disease  
N19 – Unspecified kidney failure |
| 7,854       | Epilepsy     | G40 – Epilepsy  
G41 – Status epilepticus |

**Neglected Tropical Diseases**

<table>
<thead>
<tr>
<th>Global DALYs</th>
<th>Index Disease</th>
<th>Name/ICD-10 Classifications</th>
</tr>
</thead>
</table>
| 5,941       | Lymphatic filariasis | B74.0 – Filariasis due to Wuchereria bancrofti  
B74.1 – Filariasis due to Brugia malayi  
B74.2 – Filariasis due to Brugia timori |
| 4,013       | Soil transmitted helminthiasis | B76 – Hookworm diseases  
B77 – Ascariasis  
B78 – Strongyloidesis  
B79 – Trichuriasis  
B80 – Enterobiasis  
B81 – Other intestinal helminthiases, not elsewhere classified |
| 1,974       | Leishmaniasis | B55 – Leishmaniasis |
| 1,875       | Food-borne trematodiases | B66.0 – Opisthorchiasis  
B66.1 – Clonorchiasis  
B66.3 – Fascioliasis  
B66.4 – Paragonimiasis |
| 1,707       | Schistosomiasis | B65 – Schistosomiasis [bilharziasis] |
| 1,673       | Trypanosomiasis | B56 – African trypanosomiasis |
| 1,462       | Rabies       | A82 – Rabies |
| 1,334       | Trachoma     | A71 – Trachoma |
| 670         | Dengue       | A90 – Dengue fever [classical dengue]  
A91 – Dengue haemorrhagic fever |
<p>| 503         | Cysticercosis | B69 – Cysticercosis |
| 430         | Chagas disease | B57 – Chagas disease |</p>
<table>
<thead>
<tr>
<th>Global DALYs</th>
<th>Index Disease</th>
<th>Name ICD-10 Classifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>389 Onchocerciasis</td>
<td>B73 – Onchocerciasis</td>
</tr>
<tr>
<td>13</td>
<td>194 Leprosy</td>
<td>A30 – Leprosy [Hansen disease]</td>
</tr>
<tr>
<td>14</td>
<td>144 Echinococcosis</td>
<td>B67 – Echinococcosis</td>
</tr>
<tr>
<td>15</td>
<td>NA Buruli Ulcer</td>
<td>A31.1 – Cutaneous mycobacterial infection</td>
</tr>
<tr>
<td>16</td>
<td>NA Yaws</td>
<td>A66 – Yaws</td>
</tr>
<tr>
<td>17</td>
<td>NA Dracunculiasis</td>
<td>B72 – Dracunculiasis</td>
</tr>
</tbody>
</table>

**Maternal Health Conditions**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
</table>
| 1 | 7,424 Abortion | O00 – Ectopic pregnancy  
|   |               | O01 – Hydatidiform mole  
|   |               | O02 – Other abnormal products of conception  
|   |               | O03 – Spontaneous abortion  
|   |               | O04 – Medical abortion  
|   |               | O05 – Other abortion  
|   |               | O06 – Unspecified abortion  
|   |               | O07 – Failed attempted abortion  |
| 2 | 6,535 Maternal sepsis | O85 – Puerperal sepsis  
|   |               | O86 – Other puerperal infections  |
| 3 | 4,439 Maternal haemorrhage | O44 – Placenta praevia  
|   |               | O45 – Premature separation of placenta [bruption placentae]  
|   |               | O46 – Antepartum haemorrhage, not elsewhere classified  
|   |               | O67 – Labour and delivery complicated by intrapartum haemorrhage, not elsewhere classified  
|   |               | O72 – Postpartum haemorrhage  |
| 4 | 2,882 Obstructed labour | O64 – Obstructed labour due to malposition and malpresentation of fetus  
|   |               | O65 – Obstructed labour due to maternal pelvic abnormality  
|   |               | O66 – Other obstructed labour  |
| 5 | 1,888 Hypertensive disorders of pregnancy | O10 – Pre-existing hypertension complicating pregnancy, childbirth and the puerperium  
|   |               | O11 – Pre-existing hypertensive disorder with superimposed proteinuria  
|   |               | O12 – Gestational [pregnancy-induced] oedema and proteinuria without hypertension  
|   |               | O13 – Gestational [pregnancy-induced] hypertension without significant proteinuria  
|   |               | O14 – Gestational [pregnancy-induced] hypertension with significant proteinuria  
|   |               | O15 – Eclampsia  
|   |               | O16 – Unspecified maternal hypertension  |
| 6 | N/A Contraceptive methods | Combined hormonal contraceptives, progestogen-only contraceptives, emergency contraceptive pills, intrauterine devices (IUD), copper emergency IUD, barrier methods (condoms, spermicide, diaphragm with spermicide, cervical cap)  |

**Neonatal Health Conditions**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
</table>
| 1 | 44,307 Prematurity and low birth weight | P05 – Slow fetal growth and fetal malnutrition  
|   |               | P07 – Disorders related to short gestation and low birth weight, not elsewhere classified  
|   |               | P22 – Respiratory distress of newborn  
|   |               | P27 – Chronic respiratory disease originating in the perinatal period  
<p>|   |               | P28 – Other respiratory conditions originating in the perinatal period  |</p>
<table>
<thead>
<tr>
<th>Global DALYs</th>
<th>Index Disease</th>
<th>Name ICD-10 Classifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Birth asphyxia and birth trauma</td>
<td>P03 – Fetus and newborn affected by other complications of labour and delivery</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P10 – Intracranial laceration and haemorrhage due to birth injury</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P11 – Other birth injuries to central nervous system</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P12 – Birth injury to scalp</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P13 – Birth injury to skeleton</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P14 – Birth injury to peripheral nervous system</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P15 – Other birth injuries</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P20 – Intrauterine hypoxia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P21 – Birth asphyxia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P24 – Neonatal aspiration syndromes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P25 – Interstitial emphysema and related conditions originating in the perinatal period</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P26 – Pulmonary haemorrhage originating in the perinatal period</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P29 – Cardiovascular disorders originating in the perinatal period</td>
</tr>
<tr>
<td>3</td>
<td>Neonatal infections and other conditions</td>
<td>P00 – Fetus and newborn affected by maternal conditions that may be unrelated to present pregnancy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P02 – Fetus and newborn affected by complications of placenta, cord and membranes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P04 – Fetus and newborn affected by noxious influences transmitted via placenta or breast milk</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P08 – Disorders related to long gestation and high birth weight</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P23 – Congenital pneumonia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P35 – Congenital viral diseases</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P36 – Bacterial sepsis of newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P37 – Other congenital infectious and parasitic diseases</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P38 – Omphalitis of newborn with or without mild haemorrhage</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P39 – Other infections specific to the perinatal period P50 – Fetal blood loss</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P50 – Fetal blood loss</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P51 – Umbilical haemorrhage of newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P52 – Intracranial nontraumatic haemorrhage of fetus and newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P53 – Haemorrhagic disease of fetus and newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P54 – Other neonatal haemorrhages</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P55 – Haemolytic disease of fetus and newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P56 – Hydrops fetalis due to haemolytic disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P57 – Kernicterus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P58 – Neonatal jaundice due to other excessive haemolysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P59 – Neonatal jaundice from other and unspecified causes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P60 – Disseminated intravascular coagulation of fetus and newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P61 – Other perinatal haematological disorders</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P70 – Transitory disorders of carbohydrate metabolism specific to fetus and newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P71 – Transitory neonatal disorders of calcium and magnesium metabolism</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P72 – Other transitory neonatal endocrine disorders</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P74 – Other transitory neonatal electrolyte and metabolic disturbances</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P75 – Meconium ileus in cystic fibrosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P76 – Other intestinal obstruction of newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P77 – Necrotizing enterocolitis of fetus and newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P78 – Other perinatal digestive system disorders</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P80 – Hypothermia of newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P81 – Other disturbances of temperature regulation of newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P83 – Other conditions of integument specific to fetus and newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P90 – Convulsions of newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P91 – Other disturbances of cerebral status of newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P92 – Feeding problems of newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P93 – Reactions and intoxications due to drugs administered to fetus and newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P94 – Disorders of muscle tone of newborn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P95 – Fetal death of unspecified cause</td>
</tr>
<tr>
<td></td>
<td></td>
<td>P96 – Other conditions originating in the perinatal period</td>
</tr>
</tbody>
</table>
Appendix 3: References, Definitions & Acronyms
References cited in the text of this report

2. Thomson Reuters 2012.
Definitions

Access Initiative
[working definition, for purposes of measurement]
An act, strategy, activity or programme aimed at improving the affordability, accessibility, and/or quality of health products to the end user.

Adaptive Product
Research in the development of new version of existing products, aimed at modifying those products to specifics of a local environment (including geographic, social, demographic, or other characteristics) that form barriers to access of existing products. Development of heat-resistant formulations, fixed-dose combinations and paediatric formulations are examples of adaptive R&D activities. This excludes minor adjustments that do not meet medical or practical local needs.77

Advocacy
Efforts by an individual, company or organisation to promote positive action towards improving health by educating and/or creating awareness among the public (e.g., civil education, public campaigns) or legislators. Advocacy does not support or oppose a specific issue of legislation, but rather informs the community on the health issue at hand.23-28

Affordability
[working definition, for purposes of measurement]
The end user’s ability-to-pay for products. This is taken into account in the Index when assessing pricing strategies for products.29-31

Anti-competitive Behaviour
Any practice by a company or group of companies that has, is intended to have, or is likely to have, the effect of restricting, distorting or preventing competition in order to maintain or increase their market position and/or profits. Anti-competitive behaviour leads to disadvantage or detriment of competitors, customers and suppliers such that higher prices, reduced output, less consumer choice, loss of economic efficiency and misallocation of resources (or combinations thereof) are likely to result.34-35

Audit
An internal or external examination of an organisation’s accounts, processes, functions and performance to produce an independent and credible assessment of their compliance with applicable laws, regulations and audits.36

Bolar Provision
Flexibility of the TRIPS Agreement which allows for countries to permit manufacturers to use a patented invention to obtain marketing approval before expiry of the patent and without the permission of the patent owner. The generic producers can then market their versions as soon as the patent expires.37,38

Breaches
Acts that are in violation/disregard of or non-compliant with laws, rules, guidelines or codes.36,39-41

Bribery
The offering, promising, giving, accepting or soliciting of an advantage as an inducement for an action which is illegal, unethical or a breach of trust. Inducements can take the form of gifts, loans, fees, rewards or other advantages (taxes, services, donations, etc.). Facilitation payment is a form of bribery and is defined as a payment (money, goods or services) to a government official to perform or speed up the performance of an existing duty.36,42

Clinical Trial Phases
The phases of tests in medical research and drug development that generate safety and efficacy data for health interventions.
• Phase I: These studies a study health intervention (e.g. medicine) is investigated in a small group of healthy volunteers. This phase is to determine the safety profile of the intervention (and how medicines can be metabolised and excreted).
• Phase II: In these initial studies a study medicine is investigated in a small group of patients to determine efficacy to treat a specific condition and determine safety profiles.
• Phase III: During this phase the efficacy and safety of a health intervention (e.g. medicine) is studied in different large patient populations. Different doses are tested and its efficacy and safety are compared to other therapeutic agents. When favourable results are demonstrated in this phase, regulatory approval for marketing can be obtained.
• Phase IV: These are studies that are conducted after market approval. Typically, they investigate risks, benefits and optimal use in a large population.79

Code of Conduct
Statement of principles, values and rules that establishes a set of expectations and standards on responsible practices by an organisation, government body, company, affiliated group or individual. This includes minimal levels of compliance and disciplinary actions for the organisation, its staff and volunteers.38

Collaborative Research
Research performed jointly by more than two parties where knowledge and/or expertise and resources are shared towards one or more common goals. This could involve academic institutions, government agencies and divisions, pharmaceutical companies, biotechnology companies and other public or private organisations.

Company Size
[working definition, for purposes of measurement]
Size of corporations based on revenues. This excludes all subsidiaries with non-pharmaceutical activities, unless otherwise stated.
Compound/Molecule Libraries
[working definition, for purposes of measurement]
Collections of molecules/compounds used to explore complex disease pathways and to assist in the characterisation of disease targets that may be candidates for further development into health interventions.

Compulsory Licence
A formal ruling set by law or arbitration by a government to allow a third party (e.g., pharmaceutical manufacturer) to produce a patented product or use a patented process without needing to obtain consent of the patent owner.80

Conflict of Interest
A situation where a professional or a company has a vested interest that creates a risk that professional judgement or actions will be unduly influenced. The interests at stake could be, for example, money, status, knowledge or reputation.67,68

Corruption
The abuse of entrusted power for private or corporate gain. Corruption can be classified as grand, petty and political, depending on the amounts of money lost and the sector where it occurs;
• Grand Corruption: Acts committed at a high level of government that distort policies or the central functioning of the state, enabling leaders to benefit at the expense of the public health good.
• Petty Corruption: Everyday abuse of entrusted power by low- and mid-level public officials in their interactions with ordinary citizens and healthcare professionals, who often are trying to receive or provide basic health services and products in places like hospitals, schools, and other community organisations.
• Political Corruption: Manipulation of policies, institutions and rules of procedure in the allocation of health resources and financing by political decision makers, who abuse their position to sustain their power, status and wealth.36

Country Classifications
[working definition, for purposes of measurement]
Categorisations of countries based on the UN Human Development Index, UN Department of Economic and Social Affairs classification and on the income level categories according to the World Bank. The relevant categories used are (~with source):
• Least Developed Countries (LDC) – UN Department of Economic and Social Affairs
• Low-income countries (LIC) – World Bank
• Lower-middle-income country (LMIC) – World Bank
• Upper-middle-income countries (UMIC) – World Bank
• High income – (non) OECD countries – World Bank
• Low human development countries (LHDC) – UN Human Development Index
• Medium human development countries (MHDC) – UN Human Development Index
• High human development countries (HHDC) – UN Human Development Index

Data Exclusivity
Protection of originator pharmaceutical company’s data preventing other parties from using these data for a commercial purpose. Concretely, this protection prevents other parties from using these data for a commercial purpose. Concretely, this protection prevents generics product manufacturers from proceeding to clinical trials and health authorities from evaluating generic product market authorisation applications during this period.79

Declaration of Helsinki
A set of principles regarding human experimentation developed for members of the medical community. This code of conduct is for ethical clinical trial conduct, and essential principles revolve around respect for the individual and the right to make informed decisions. It aims to protect the rights and wellbeing of the individual participating in human research. The Declaration of Helsinki was initially adopted in 1964 as a reaction to the lack of a general accepted code of conduct for human research and is frequently updated (last update: 201381).

Disability Adjusted Life Year (DALY)
One DALY can be thought of as one lost year of ‘healthy’ life. The sum of these DALYs across the population, or the burden of disease, can be thought of as a measurement of the gap between current health status and an ideal health situation where the entire population lives to an advanced age, free of disease and disability.82

Doha Declaration on the TRIPS Agreement and Public Health
An agreement between governments affirming that the TRIPS agreement should not prevent TRIPS member countries from protecting public health interests. The Doha Declaration (14 November 2001) clarified the flexibilities of TRIPS member states in navigating pharmaceutical patents. It granted member states the right to grant compulsory licenses; to determine what constitutes a national emergency or extreme urgency; and that each member is free to establish its own regime for the exhaustion of intellectual property rights.83

Drug Diversion
Channelling lower-priced medicines from developing countries into developed countries or from lower income segments to high-income segments, or from public to private sector, within a country.84

Drug Recall
Actions taken by a company or medicine regulatory authority to remove from the market products or batches of products that are found to be either defective or potentially harmful. Recalls include those due to both packaging and quality or safety issues. The index captures those recalls of products that are subject to GMP standards, i.e. medicines, vaccines, microbicides and other medicinal products for human use.85
Equitable Pricing
[working definition, for purposes of measurement]
A targeted pricing strategy that ensures the poor gain access to medicine by affordable pricing that is locally appropriate, implemented on a case-by-case basis. 87

Ethical Clinical Trial Conduct
Guidelines regarding ethical and scientific quality standards for designing, conducting, recording, and reporting findings from trials that involve participation of human subjects. Rights, safety, and well-being of the trial subjects are the most important considerations and should prevail over interests of science and society. Principles from Good Clinical Practice and the Declaration of Helsinki, among others, are used as guidelines to guarantee ethical clinical trial conduct. 86

Ethical Marketing
Promotional activities (both hidden and public) that are aimed at the general public, patients, healthcare professionals/students and opinion leaders in such a way that transparency, integrity, accuracy, clarity and completeness of information can be ensured. 45-48

Evergreening of Patents and Patent Clusters
Patent clusters around an existing medicine is patenting of new forms or other minor variations of existing products that have no additional therapeutic value and display limited inventiveness. This can be used to prolong patent protection in an inappropriate manner, creating a negative effect on access to medicines, as well as on further innovation – a strategy referred to as ‘evergreening’. The Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH) defined evergreening as a term popularly used to describe patenting strategies “when, in the absence of any apparent additional therapeutic benefits, patent holders use various strategies to extend the length of their exclusivity beyond the 20-year patent term”. 74

Generics
A pharmaceutical product which has the same qualitative and quantitative composition in active substances and the same pharmaceutical form as the reference medicinal product, and whose bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies. 73

G-Finder References for Disease Scope
G-FINDER only includes infectious diseases that follow three criteria:
- Disproportionally affect the developing world
- There is a need for new products (i.e. there is no existing product OR improved or additional products are needed)
- There is market failure (i.e. there is insufficient commercial market to attract R&D by private industry). 88

Good Clinical Practice (GCP)
An international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible. GCP is set up by the International Conference on Harmonisation (ICH) that aims to harmonise technical requirements for registration of medicines for human use globally. 49

Good Manufacturing Practices (GMP)
Guidelines for ensuring that products are consistently produced and controlled according to quality standards. It is designed to minimise the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product. WHO has established detailed guidelines for GMP. Many countries have formulated or harmonised their own requirements for national GMP, often based on WHO GMP. 50

Healthcare Infrastructure
Basic physical and organisational structures needed to deliver health care. This extends from healthcare-related services provided to communities, hospitals and other healthcare-related facilities. 90-93

Index Country
Any country covered by the 2014 Index. Please refer to the ‘Geographic Scope’ section for more details.

Index Disease
Any disease covered by the 2014 Index. Please refer to the ‘Disease Scope’ section for more details.

(Inter)National Health Priority
Areas for action stated either by national governments or by multilateral organisations, such as the Millennium Development Goals. 91

Impact Assessment
[working definition, for purposes of measurement]
Process of predicting and evaluating the effects that a policy, programme or activity has on the health of a population, and the distribution of those effects within the population. This includes the effect on patient outcomes, epidemiology, healthcare infrastructure and other effects that relate to public health and can include also wider socio-economic impacts. 69-70

In-house Research
Research into the development of innovative or adaptive compounds that is executed by the research-based pharmaceutical company without outsourcing to contract research organisations.

Innovation
[working definition, for purposes of measurement]
Leading and unique practices.

Innovative Product
Research aimed at developing new products for one or more unmet medical needs (in contrast to Adaptive Product). 77
Intellectual Property (IP)
The rights given to persons over the creations of their minds. They usually give the creator an exclusive right over the use of his/her creation for a certain period of time in exchange of publication of the innovation. Industrial IP is protected traditionally to stimulate innovation, design and the creation of technology. In this category fall inventions (protected by patents), industrial designs and trade secrets. The protection is usually given for a finite term (typically 20 years in the case of patents).41

Inter-Country* Equitable Pricing
* All Index Countries where a product is used to treat Index Diseases will come into this category.
A targeted pricing scheme at the country level which takes into account affordability for the poorest countries.84, 87

Intra-Country* Equitable Pricing
* All Index Countries where a product is used to treat Index Diseases will come into this category.
A targeted pricing scheme where a company has different pricing tiers within an Index Country based on the socioeconomic profiles of different population segments, taking into account affordability for the poorest segments in the country.84, 87

Lobbying
Any activity carried out to influence a government or institution’s policies and decisions in favour of a specific cause or outcome. Direct lobbying occurs via communication with a legislator, legislative staff, legislative body or government employee who may participate in the formulation of legislation. Grass-roots lobbying is an attempt to influence legislation by encouraging the public to contact legislators about a specific issue. Even when allowed by law, these acts can become distorting if disproportionate levels of influence exist.23-26,28,36

Long-term
[working definition, for purposes of measurement]
A project, commitment, engagement, initiative, or plan is considered long-term when its duration is 5 years or longer.

Molecules
[working definition, for purposes of measurement]
Any New Chemical Entities (NCEs), New Biological Entities (NBEs) or any new drug or vaccine candidates.

Multi-drug Donations
[working definition, for purposes of measurement]
A gift of products for which there is no clear, defined long-term strategy. This may include a company donating a range of medicines based on stock availability, which may or may not be based on the explicit needs of a country. Donations made during emergency situations, such as conflict and natural disasters, are included here.

National Pharmacovigilance Programmes
Nationwide systems or projects (in Index Countries) to establish and support a database of adverse drug reactions for informed regulatory decision making; and to improve the rational and safe use of medical drugs, the assessment and communication of the risks and benefits of drugs on the market, and the education of patients. A comprehensive national pharmacovigilance system should include efficient surveillance, effective communication methods, and collaboration with the relevant stakeholders to ensure pharmacovigilance activities are incorporated.53

New Drug Application (NDA)
A formal request to a regulatory authority for market authorisation of a medicine. An NDA contains all the pre-clinical and clinical information obtained during the testing phase.95

Non-Assert Declaration
A legally binding commitment that contains an explicit set of conditions, including permitted actions and designated territories, for which the patent owner commits not to enforce patent rights. This allows for a generic version of a patent protected product to be produced in a resource-limited setting.77, 94

Non-Exclusive Voluntary Licencing (NEVL)
A contract in which the patent holder allows the contracting party to use the patent, either against a payment of royalties or free of charge for a defined period of time.77, 94

Originator Company
A company that has at least one product authorised worldwide for marketing (normally as a patented product).75

Outside the Value Chain
[working definition, for purposes of measurement]
Activities beyond the scope of the company’s normal operations and distribution channels.

Parallel Import
Import of a patented or trademarked product from a country where it is marketed, usually to obtain a lower price.77

Patent
An intellectual property right providing an inventor with a legal monopoly to prevent others from making, using, or selling the new invention for a defined period of time, subject to a number of exceptions. Also includes the obligation to publish the invention. A patent does not automatically mean the product is safe for consumers or that it can be supplied. Patentied medicines still have to go through rigorous testing and approval before they can receive market authorisation.37
Portfolio of patents and other relevant intellectual property rights held by various actors made available through a joint licensing scheme to third parties (e.g., generics manufacturers) against the payment of royalties.\textsuperscript{95}

Patent Thicketing
A strategy used to block competition by filing a dense web of overlapping patents that extensively covers a single technological niche, where a competitor becomes entangled in a ‘thicket’ of patents. This obstructs entry to market, thereby impeding access.\textsuperscript{97}

Performance Management Systems
Formal and informal mechanisms, tools, processes and networks used by organisations to manage and reward performance in line with corporate and functional strategies and goals. This includes performance measurement, i.e., collecting, analysing and reporting information regarding the performance of an individual, group or organisation in order to track progress towards set goals.

Period of Analysis
For the 2014 Index, the time period for which data will be analysed covers fiscal years 2012 and 2013, where company activities must be ongoing between June 2012 and the end of May 2014, as this is the cycle of the Index. Programmes that have ended before June 1st 2012 are not included. Additionally, any activities that were already assessed in the 2012 Index will not be scored as innovative or new in relevant indicators. The Index team assesses most recent policies, codes and stances, up to final submission.

Pharmacovigilance
The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. Medicines need to be monitored, and any adverse drug reactions need to be remedied in a timely manner through pharmacovigilance systems.\textsuperscript{98}

(Corporate) Political Contributions
Any direct or indirect gift, either in cash or in kind, to support a political cause or an individual. Examples include gifts of property or services, advertising or promotional activities endorsing a political party, and the purchase of tickets to fundraising events.\textsuperscript{96}

Pre-clinical Research
Research aimed at assessing potential efficacy and toxicity prior to testing a product. Typically, both \textit{in vitro} and \textit{in vivo} tests are performed. \textit{During in vitro} tests data is collected to determine chemical and biological properties of products in an isolated laboratory setting. When results are positive, \textit{in vivo} tests are used to determine toxicity and ability to treat or prevent a particular disease or symptom in living animals.\textsuperscript{58,59}

Prequalification of Medicines
A service provided by WHO to assess the quality, safety and efficacy of certain medicinal products (mainly for HIV/AIDS, TB, malaria and reproductive health) for procurement by UN agencies and/or from UN funds.\textsuperscript{88}

Pro-access
[\textit{working definition, for purposes of measurement}]
An adjective to ensure positive provisions that address public health needs. A pro-access licence will have explicit terms embedded within it that ensure timely medicine development and market registration, safe and acceptable products delivered to populations who need them. A pro-access price is one that is affordable to the lowest socio-economic quintiles and commercial imperatives will be balanced against patient needs.

Products
[\textit{working definition, for purposes of measurement}]
Products, technologies or commodities, which are described in the product type scope: medicines, therapeutic vaccines, preventive vaccines, diagnostics, microbicides, vector control products, and platform technologies.

Rational Use
The scientifically sound use of medicines. Rational use requires that patients receive the appropriate medicine, in the proper dose, for an adequate period of time, and at a cost which is affordable to them and their community.\textsuperscript{51}

Revenue
The ‘top line’ or ‘gross income’ figure from which costs are subtracted to determine net income. The Index 2014 looks at total sales revenues generated over the past three years (2011-2013).

Single-drug Donations
[\textit{working definition, for purposes of measurement}]
A gift of products for which a defined strategy exists as to the type, volume, and destination of donated products. Single-drug donations are based on long-term, targeted donation programmes based on country needs, usually targeted at one disease.

Socially Responsible Licencing (SRL)
A licencing concept that involves various principles or provisions (such as territorial scope, pricing and milestones for delivery) in licencing agreements aiming to achieve certain social outcomes such as access to, and affordability of, crucial technologies for people in need.\textsuperscript{73,94}
Spurious/Falsely-labeled/Falsified/Counterfeit (SFFC) medicines
The term counterfeit medical product describes a product with a false representation of its identity and/or source. This applies to the product, its container or other packaging or labelling information. Counterfeiting can apply to both branded and generic products. Substandard batches of or quality defects or non-compliance with Good Manufacturing Practices/Good Distribution Practices (GMP/GDP) in legitimate medical products must not be confused with counterfeiting. Medical products (whether generic or branded) that are not authorised for marketing in a given country but authorised elsewhere are not considered counterfeit.76

Strategic Pillar
As part of the Index’s analytical framework, the indicators under each Technical Area are broken down into four Strategic Pillars – Commitments, Transparency, Performance and Innovation.

Subsidiary
[working definition, for purposes of measurement]
A company that is owned or controlled by another firm or company79; subsidiaries include firms in which a company owns more than 50% of the outstanding voting stock, as well as firms in which a company has the power to direct or cause the direction of the management and policies.

Sustainable
[working definition, for purposes of measurement]
Targeted activities aimed at enhancing access locally in the long run.

Technical Area
As part of the Index’s analytical framework, the seven major Technical Areas under which the companies are analysed in Index 2014 are: General Access to Medicine Management; Public Policy & Market Influence; Research & Development; Pricing, Manufacturing & Distribution; Patents & Licencing; Capability Advancement in Product Development & Distribution; and Product Donations & Philanthropic Activities.

Technology
An application of organised knowledge and skills in the form of products, devices, procedures and systems developed to solve a health problem and improve quality of lives (see product scope for detailed overview of included technologies).60, 81

Technology Transfer
The process by which any party gains access to another party’s technical information or know-how and successfully learns and absorbs it into its research, development or manufacturing processes.100

Tiered Pricing
A pricing scheme where a company adapts product prices based on the purchasing power of consumers in different geographic or socioeconomic segments. Tiered pricing takes into account affordability of medicines and other products for low-income segments, and is therefore a form of equitable pricing.87

Trade-Related Aspects of Intellectual Property Rights (TRIPS)
A multilateral agreement that was issued to protect Intellectual Property rights around the world under international rules, where all countries must make patents eligible for pharmaceutical products and processes. The World Trade Organization’s TRIPS Agreement covers five broad issues:
- How basic principles of the trading system and other international intellectual property agreements should be applied
- How to give adequate protection to intellectual property rights
- How countries should enforce those rights adequately in their own territories
- How to settle disputes on intellectual property between members of the WTO
- Special transitional arrangements during the period when the new system is being introduced.90

Transparency
Characteristic of a company of providing clear disclosure of information regarding corporate governance and accountability, conflicts of interest, medicines policies, licencing details, product-specific pricing schemes, clinical trial conduct and data and market authorisations in a comprehensible, accessible and timely manner towards the general public and healthcare professionals.36, 48, 62

Treatment
First-line treatment: Refers to standard medicines that are the first choice for health interventions. This choice is based on favourable clinical results in a large population.
Second-line treatment: When efficacy of first-line therapy is low or when it induces too many adverse effects, additional medicines may be added to or substitute previously initiated treatment.

TRIPS+ (or TRIPS Plus)
Measures contained in multilateral, regional, plurilateral or national intellectual rules and practices that protect intellectual property rights beyond the minimum standards set out in the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement and may hinder Index Country governments from acting in the public interest. This covers both those activities aimed at increasing the level of protection for right holders beyond that which is given in the TRIPS Agreement and those measures aimed at reducing the scope or effectiveness of limitations on rights and exceptions under the TRIPS Agreement.77

Whistle-blower
An informant who exposes wrongdoing by a company that threatens public interest, such as neglect or abuse, within an organisation, either internally or publicly, in the hope of stopping it.36, 66
References cited in Definitions

23 Technical Assistance for Civil Society Organizations. Advocacy and lobbying. 

24 Marion County Commission on Youth Inc.. Advocacy -vs- Lobbying. 

25 Young Adult Library Services Association. Advocacy and Lobbying – What’s the difference? 


http://www.un.org/popin/regional/asiapac/fiji/advocacy.htm%20TO%20ADVOCACY.

28 Northeast Ohio Medical University. Public Health Library Guides - Advocacy & Lobbying, what are they? 


32 Australian Competition & Consumer Commission. Anti-competitive Agreements. 

33 UK office of fair trading. Competing fairly - An introduction to the laws on anti-competitive behaviour, 2005. 

34 The Times 100. Business Case Studies - The importance of competition policy: Anti-competitive practices. 

35 OECD. OECD Glossary of Statistical Terms - Anticompetitive practices. 


37 WTO, 2006. TRIPS and pharmaceutical patents - Fact Sheet. 

38 WTO. Intellectual property: protection and enforcement. 

http://wordnet.princeton.edu/perl/webwn?s=code+of+conduct&sub=Search+WordNet&o2=&o0=1&o8=1&d0=1&h=0000.


42 Serious Fraud Office, 2012. Facilitation payments. 


44 WHO. Prepublication draft equitable pricing of newer essential medicines for developing countries: 2003. 
http://apps.who.int/medicinedocs/en/m/abstract/Js18815en/.

45 Danish Consumer Ombudsman. DCO speech on hidden advertising, ICcen-Meeting, Australia. 
http://www.consumerombudsmandk/Public-Relations/so/covertadvertising/hidenadvertising.

http://www.consumerombudsmandk/Public-Relations/so/covertadvertising/hidenadvertising.

47 IFPMA. Ensuring Ethical Promotion of Pharmaceutical Products: The IFPMA Code. 

http://ichgcp.net/.

49 International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. Good clinical practice. 
http://ichgcp.net/.
Appendix 3

50 WHO. GMP Question and Answers.

51 WTO. Intellectual Property (TRIPS) - what are intellectual property rights?


http://apps.who.int/medicinedocs/documents/s17085e/s17085e.pdf.

54 WHO. National Pharmacovigilance Centres.


58 UK Medicines and Healthcare Products Regulatory Agency. Pre-clinical research.
http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Adviceandinformationforconsumers/MymedicineFromlaboratorytopharmacyshelf/Pre-clinicalresearch.


http://www.wto.org/english/tratop_e/trips_e/trilat_5feb13_e.htm.

http://www.who.int/topics/technology_medical/en/.

62 OECD. OECD Glossary of Statistical Terms - Transparency.

63 Médecins Sans Frontières. TRIPS, TRIPS Plus and Doha.
http://www.msfasccess.org/content/trips-trips-plus-and-doha.

64 Nicol, D., Owoeye, O., 2013; 91(7). Using TRIPS flexibilities to facilitate access to medicines.
http://www.who.int/bulletin/volumes/91/7/12-115865/en/.

65 WTO, 2006. Intellectual property (TRIPS) and pharmaceuticals.

http://wordnetweb.princeton.edu/perl/webwn?s=whistleblower&sub=Search+WordNet&o2=&o0=1&o8=1&o1=1&o7=&o6=&o5=&o9=&o4=&h=.

67 Institute on Medicine as a Profession (IMAP). Defining the Problem of Conflict of Interest.

68 Investopedia. Conflict of interest.

69 WHO. Definitions of Health Impact Assessment.

70 WHO. Glossary of terms used in Health Impact Assessment.


76 WHO, Frequently Asked Questions, Spurious/Falsely-Labeled/Falsified/Counterfeit (SFFC).


Appendix 3


Acronyms

AIDS Acquired Immune Deficiency Syndrome
CDD Collaborative Drug Discovery
CRO Contract Research Organisation
CIPHI Commission on Intellectual Property Rights, Innovation and Public Health
DALY Disability Adjusted Life Year
DFID UK Department for International Development
EMA European Medicines Agency
ERC Expert Review Committee
FDA Food and Drug Administration
GCP Good Clinical Practice
GMP Good Manufacturing Practices
HDI Human Development Index [UN]
HIV Human Immunodeficiency Virus
ICH International Conference on Harmonisation
IHDI Inequality-Adjusted Human Development Index [UN]
IP Intellectual Property
LDC Least Developed Country [UN]
LHDC Low Human Development Country [UN]
LIC Low Income Country [WB]
LMIC Lower Middle Income Country [WB]
MDG Millennium Development Goal
MHDC Medium Human Development Country [UN]
MIC Middle-Income Country [WB]
MoH Ministry of Health
NAD Non-Assert Declaration
NBEs New Biological Entities
NCEs New Chemical Entities
NEVL Non-Exclusive Voluntary Licencing
NEVLs Non-Exclusive Voluntary Licences
NGO Non-Governmental Organisation
NTD Neglected Tropical Disease
OSDD Open Source Drug Discovery
R&D Research and Development
SRL Socially Responsible Licencing
SFFC Spurious/Falsely-labelled/Falsified/Counterfeit
TRIPS Trade-related Aspects of Intellectual Property Rights
TSC Technical Subcommittee
UN United Nations
WB World Bank
WHO World Health Organization
WIPO World Intellectual Property Organization
WTO World Trade Organization

Disclaimer
As a multi-stakeholder and collaborative project, the findings, interpretations and conclusions expressed herein may not necessarily reflect the views of all members of the stakeholder groups or the organisations they represent. The report is intended to be for information purposes only and is not intended as promotional material in any respect. The material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The report is not intended to provide accounting, legal or tax advice or investment recommendations. While based on information believed to be reliable, no guarantee can be given that it is accurate or complete. All opinions expressed herein are subject to change without notice.

Copyright
No part of this report may be reproduced in any manner without the written permission of the Access to Medicine Foundation.

Photography
Wim Leereveld, Jayasree Iyer
Yara InMedia, The Netherlands

Design
Explanation Design BV, The Netherlands